Cardiology: Recent Episodes
ReachMD
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Joel M. Gelfand, MD, MSCE, FAAD
Guest: Michael S. Garshick, MD
Inflammatory skin diseases like psoriasis don’t just affect the skin—they can often reflect broader cardiovascular risks. Given the overlap between dermatology and cardiology, knowing how to spot warning signs early and what steps to take during routine visits is key to comprehensive care. Joining Dr. Mary Cheeley to discuss the connection between the skin and the heart are Drs. Joel Gelfand and Michael Garshick. Dr. Gelfand is a dermatologist at the University of Pennsylvania and the Director of the Psoriasis and Phototherapy Treatment Center and the Center for Clinical Sciences in Dermatology. Dr. Garshick is a cardiologist and the Director of the Cardio-Rheumatology Program at NYU Langone Health, as well as an Assistant Professor of Medicine and Dermatology at NYU Grossman School of Medicine.
Guest: Michael Crotty, MB, BCh, BAO
Guest: Barbara McGowan, PhD, MBBS
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Guest: Michael Crotty, MB, BCh, BAO
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Guest: Michael Crotty, MB, BCh, BAO
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Guest: Michael Crotty, MB, BCh, BAO
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Guest: Michael Crotty, MB, BCh, BAO
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.
This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Host: Rishi Wadhera, MD, MPP, Mphil
This on-demand knowledge primer explores key challenges and evidence-based strategies for improving atherosclerotic cardiovascular disease (ASCVD) management in rural populations. Led by two expert faculty members, the program provides a comprehensive overview of disparities in ASCVD care, guideline-directed therapies, and practical approaches to overcoming barriers in rural settings. Participants will gain essential knowledge to enhance patient outcomes and optimize cardiovascular care in underserved communities.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Saurabh Malhotra, MD, MPH
Guest: Kevin Alexander, MD
Guest: Tawfiq Al-lahham, MD
Guest: Sarah Cuddy, MD
Guest: Angela Dispenzieri, MD
Guest: Anita D’Souza, MD
Guest: Foluso Fakorede, MD
Guest: Mazen Hanna, MD
Guest: Isabelle Lousada
Guest: Ahmad Masri, MD, MS
Guest: Mathew S. Maurer, MD
Guest: Matthew Parker, MD
Guest: Frederick Ruberg, MD
Guest: Andrew Staron, MD
Guest: Prem Soman, MD, PhD
Guest: Jonathan Wall, PhD
Guest: Ashutosh Wechalekar, MBBS, MD
Guest: Panithaya Chareonthaitawee, MD
The Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management will consist of four virtual live sessions on March 7-9, 2025. The case-based sessions will provide an in-depth discussion of cardiac amyloidosis and its pathogenesis, diagnostic techniques and pitfalls, management strategies, mechanisms to facilitate early diagnosis, treatment and management, and challenging case studies presented by leading internationally recognized experts in transthyretin cardiac amyloidosis.
Host: Mikhail Kosiborod, MD
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their treatment. Join the experts as they explore chronic hyperkalemia management, and the role of potassium binders.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Reidenbach, PharmD, MBA
Grace Health in Michigan recently implemented the AMA MAP™ Hypertension Quality Improvement Program, and now, pharmacists play a much bigger role in helping both providers and patients. In fact, pharmacists have been able to improve adherence and outcomes through education, patient-centered care, and the use of single-pill combinations. Here with Dr. Charles Turck to share her experience with the AMA MAP™ Hypertension program is Dr. Emily Reidenbach, a pharmacist at Grace Health in Michigan.
Host: Harry Yoon, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Guest: Robert P. Frantz, MD, FACC
Guest: Vallerie V. McLaughlin, MD
Guest: Sonja Bartolomei, MD
Hear about the latest updates in risk assessment and find out how you can accurately use risk stratification to categorize patients in a timely manner to improve both their care and quality of life. You’ll also discover changing practice trends and the latest evidence that may impact your practice.
Guest: Vallerie V. McLaughlin, MD
Guest: Victor Moles, MD
Guest: Ioana Preston, MD
The landscape of medication management for patients with pulmonary hypertension (PH) has significantly changed with the introduction of combination therapy and recent trial data. This activity presents the latest evidence and breaks down new approaches to the management of PH. Join our experts to find out how your daily practice will be affected.
Host: Harry Yoon, MD
Guest: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
A concerning number of patients with atherosclerotic cardiovascular disease (ASCVD) reached suboptimal LDL-C levels between 2021 and 2022. Even with new strategies that can help lower LDL-C, an analysis of over 3 million ASCVD patients in the Family Heart Database shows that these treatments are not being properly utilized. Join Dr. Keith C. Ferdinand as he delves into an analysis of management trends among these patients, which he presented at the 2024 Family Heart Foundation Global Summit. Dr. Ferdinand is a Professor of Medicine and the Gerald S. Berenson Endowed Chair in Preventative Cardiology at the Tulane University School of Medicine in New Orleans, Louisiana.
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Guest: Vallerie V. McLaughlin, MD
Guest: Thomas Cascino, MD
Guest: Bradley A. Maron, MD
Providers face challenges when it comes to pulmonary hypertension (PH), especially when distinguishing between PAH with comorbidities and group 2 PH. In addition, PH resulting from left heart disease may further complicate diagnosis and treatment. Hear what the experts have to say about identifying and treating these patient populations.
Host: John Russell, MD
Guest: Noel Dasgupta, MD, FACC
Guest: Sami Khella, MD
Amyloidosis, often unrecognized, misdiagnosed, and either inappropriately treated or undertreated, is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. There are two prominent forms of amyloidosis misfolding of light chain proteins (AL amyloidosis) and transthyretin protein misfolding (ATTR amyloidosis). In this program, two experts in amyloidosis, cardiologist Dr. Noel Dasgupta and neurologist Dr. Sami Khella, will explain the pathophysiology of amyloidosis, describe the prognosis for patients, discuss timely patient screening and diagnostic testing, and provide updated treatment options.
Host: Pablo Garcia-Pavia, MD, PhD
Guest: Francesco Cappelli, MD
Achieving optimal outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) remains a challenge as diagnosis is often delayed. Patients have a reduced life expectancy and experience debilitating pain and poor quality of life. Hear from the experts as they review the latest information on new and emerging treatment options for transthyretin amyloidosis and how this condition affects patients with cardiomyopathy.
Host: Gates B. Colbert, MD
Guest: Michael Cui, MD, MBA, MS
Rush University Medical Center officially launched the AMA MAP™ Hypertension quality improvement program in March of 2022, and since then, blood pressure control has increased by up to 4 percent, impacting hundreds of patients. Joining Dr. Gates Colbert to talk about the implementation and impacts of the AMA MAP™ hypertension program at Rush University Medical Center is Dr. Michael Cui, Assistant Professor in the Division of General Internal Medicine and the Associate Chief Medical Informatics Officer at Rush University Medical Center in Chicago, Illinois.
Host: Raymond Townsend, MD
Guest: Melissa Magwire, RN, MSN, CDE
Guest: Michael Weber, MD
The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A1c. Similar to statins a long time ago, SGLT2 inhibitors offer many advantages for patients with potential atherosclerotic endpoints. Learn from our expert multidisciplinary panel as they explore the various approaches to treatment that can improve outcomes and quality of life in your patients with cardiorenal comorbidities.
Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Guest: Scott Solomon, MD
Guest: Mikhail Kosiborod, MD
There are limited therapeutic options for patients with heart failure with mid-range or preserved ejection fraction (HFmrEF/HFpEF). Recently, new data were released on the efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists (MRAs) in patients with HFmrEF/HFpEF. What are the outcomes of the FINEARTS-HF trial with finerenone in this patient population, and what do these findings mean for clinical practice?
Three cardiologists discuss the topic of novel therapies, with a focus on nonsteroidal MRAs, to improve cardiovascular outcomes in patients with HFmrEF/HFpEF.
Guest: David Wheeler, MB, CHB, MD, FRCP
Hyperkalemia is a common complication in patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Join Dr. David Wheeler as he explores strategies for managing hyperkalemia while optimizing treatment benefits. Learn about patient-centered communication techniques, risk factors, and treatment options. Discover the importance of ongoing monitoring and follow-up to ensure optimal management. You don’t want to miss this opportunity to improve your clinical practice and enhance patient outcomes.
Host: Jean M. Elwing, MD
Host: Nicholas Kolaitis, MD, MAS
Guest: Katharine Clapham, MD
Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to specialized care and resources. The scarcity of specialized PH centers forces reliance on general practitioners, further hampered by geographic isolation and constrained resources. These limitations make it difficult for healthcare providers to stay updated on new treatments, guidelines, and clinical trial data. To address these gaps, a strategic initiative is needed to enhance early detection, deliver insights on novel therapies, and promote multidisciplinary care through telementoring, aiming to improve PAH management in underserved rural areas.
Host: Christina Economides, MD
Guest: Brian Howard, MD
Guest: David N. Kenigsberg, MD, FACC
Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms and diminishing quality of life. Baroflex activation therapy (BAT) may be a treatment option for patients with heart failure with reduced ejection fraction. Data show clinical benefit with this treatment approach including long-term symptom improvement and reduction in all-cause death. To ensure optimal outcomes with BAT, a multidisciplinary approach is necessary. In this activity, expert faculty review the rationale for BAT therapy, the supporting clinical data, the surgical procedure for the BAT device, and best practices for optimizing a multidisciplinary approach.
Guest: Chi Liu, PhD
The field of artificial intelligence in nuclear medicine is evolving quickly with new models and approaches. Tune in with Dr. Chi Liu, Professor of Radiology and Biomedical Engineering at Yale University, to hear more about his presentation from SNMMI 2024.
Guest: Jessica Griffiths, PA-C
Guest: Anna L. Rourke, NP
The BeAT-HF clinical trial showed that Barostim plus GDMT resulted in significant and meaningful improvements in exercise capacity, functional status, and quality of life. Learn best practices from advanced practice providers for successfully integrating Barostim into your clinical practice.
Guest: John Barbieri, MD, MBA, FAAD
Patients with psoriasis die about five years younger than those without the condition, and cardiovascular disease is the leading cause of this premature mortality. Tune in to hear Dr. John Barbieri discuss strategies to identify risk factors and improve cardiovascular disease prevention in patients with psoriasis. Dr. Barbieri is an Assistant Professor of Dermatology at Brigham and Women's Hospital at Harvard Medical School in Boston.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Wilson Tang, MD
Many different artificial sweeteners are being consumed by patients; however, this discussion will focus on research around one that has been used in the food industry for a long time, called erythritol. Interestingly, it was found that patients with cardiac problems had the highest levels of erythritol levels in their blood, which prompted further studies on this association. So to learn more about the impact of artificial sweeteners on heart disease and how we can guide patients into consuming less, join Dr. Mary Katherine Cheeley as she speaks with Dr. Wilson Tang, Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Co-Author of the article, titled “The Artificial Sweetener Erythritol and Cardiovascular Event Risk,” published in Nature Medicine in February 2023.
Host: Valeria Caso, MD, PhD
Guest: Ashkan Shoamanesh, MD
How can you improve long-term secondary stroke prevention in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA)? An understanding of how to apply emerging clinical trial data is critical, as is the evaluation of potential alternative agents that could expand the therapeutic options for these patients. In this activity, our expert faculty will add to your knowledge by reviewing the coagulation cascade and the relevance of inhibiting factors XI and XIa in stroke management.
Host: Hongya Chen, PharmD
Guest: Jennifer Day, PharmD
Guest: Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM management. The program emphasizes the latest clinical insights in this evolving therapeutic landscape, addressing changes in diagnostic approaches over the last decade, and providing a nuanced perspective on ATTR-CM progression for more effective patient care. Don’t miss out on this opportunity to elevate the standard of care for your patients.
Host: Marianna Fontana, MD
Guest: Ronald Witteles, MD
Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATTR-CM in the future. They'll also discuss the use of outpatient diuretic intensification as a potential endpoint in trials and the ongoing challenge of defining and measuring “clinically meaningful benefit” for patients with ATTR-CM. Don't miss this opportunity to gain valuable insights and elevate your understanding of ATTR-CM treatment strategies!
Host: Marc P. Bonaca, MD, MPH
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Manesh R. Patel, MD
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Manesh R. Patel, MD
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Marc P. Bonaca, MD, MPH
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Daniel Gaudet, MD, PhD
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Marianna Fontana, MD
The HELIOS trials, a groundbreaking phase 3 program, are investigating the potential of vutrisiran, an RNA interference (RNAi) therapy, to combat both hereditary and wild-type ATTR amyloidosis. Building on a successful phase 1 study demonstrating vutrisiran's safety and effectiveness in reducing serum TTR, HELIOS is paving the way for a new era in ATTR treatment.
Join Dr. Marianna Fontana as she highlights the cardiac exploratory analysis of HELIOS-A and the design of HELIOS-B.
Guest: Pierre Elias, MD
In this episode, you’ll gain insights into Dr. Elias’ innovative approach, integrating technology, data science, and medicine to develop algorithms that aim to enhance accuracy in predicting cardiovascular disease while allowing them to focus on providing personalized care to their patients. This could even help diagnose patients before symptoms occur. Join health and science journalist Catherine Price as she speaks with Dr. Pierre Elias, Medical Director of Artificial Intelligence at NewYork-Presbyterian, about the future of technology in medicine.
© 2024 NewYork-Presbyterian
Guest: Christopher Petit, MD
Pulmonary vein stenosis (PVS) is a rare and challenging heart condition, which narrows blood vessels around the lungs and typically impacts newborn children. Historically, the rates of survival have been low, but with Dr. Petit leading the development of innovative techniques and treatments, the trajectory of patients’ lives could positively change. Join health and science journalist Catherine Price and Dr. Christopher Petit, Co-Director of Children’s Heart Center at NewYork-Presbyterian Morgan Stanely Children’s Hospital and Division Chief of Pediatric Cardiology at Columbia University, to discuss breakthroughs and treatments that are making a big impact on pediatric survival rates.
© 2024 NewYork-Presbyterian
Host: Bruce L. Davidson, MD, MPH
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Alfonso J. Tafur, MD, MS, MBA, RPVI
Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Alfonso J. Tafur, MD, MS, MBA, RPVI
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Bruce L. Davidson, MD, MPH
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Victor F. Tapson, MD
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Bruce L. Davidson, MD, MPH
Host: Victor F. Tapson, MD
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Scott Kaatz, DO, MSc, FACP, SFHM
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Scott Kaatz, DO, MSc, FACP, SFHM
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Deborah Siegal, MD, MSc, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Deborah Siegal, MD, MSc, FRCPC
Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.
Host: Mina K. Chung, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Manesh R. Patel, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Sean Pokorney, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Kevin Thomas, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Manesh R. Patel, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Sean Pokorney, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Manesh R. Patel, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Sean Pokorney, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Sean Pokorney, MD
The recently published 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. This program will help distill these valuable clinical guidelines to help healthcare professionals better understand these recommendations to incorporate into their clinical practice.
Host: Naomi Fisher, MD
Guest: Florian Rader, MD
Dive into the realm of hypertension management through a chapterized expert interview CME activity on ultrasound renal denervation. In the first chapter, explore the significance of addressing hypertension. Delve into the sympathetic nervous system, ultrasound renal denervation mechanism, and clinical trial data in the second chapter. The third chapter offers dual perspectives on the role of the Hypertension Center, and walks learners through the development process for effective implementation. Gain comprehensive insights from leading experts, Drs. Naomi Fisher and Florian Rader, in this educational series.
Host: Ashkan Shoamanesh, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Manesh R. Patel, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Mike Sharma, MD, MSc, FRCPC
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Valeria Caso, MD, PhD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Mikhail Kosiborod, MD
Guest: Biff F. Palmer, MD
Delve into refining the management of hyperkalemia in CKD patients and their associated comorbidities, striking a delicate balance that preserves guideline-recommended RAASi therapy. Join Dr. Biff Palmer and Dr. Mikhail Kosiborod as they guide the exploration of novel potassium binders for optimal hyperkalemia management, all while upholding the integrity of established treatment guidelines.
Host: Renuka Jain, MD
Guest: Steven Yakubov, MD, MSCAI, FACC
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
Host: Hemal Gada, MD
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: Steven Yakubov, MD, MSCAI, FACC
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
Host: Renuka Jain, MD
The Changing TAVR Landscape" is a comprehensive multiepisodic CME series addressing critical aspects of the evolving transcatheter aortic valve replacement (TAVR) landscape. Join our experts as they discuss topics on patient identification ranging from the use of echocardiography to identify symptomatic severe aortic stenosis patients to challenging case discussions, device durability, and up-to-date clinical trial data.
Host: Manesh R. Patel, MD
Host: Sean Pokorney, MD
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
Host: Manesh R. Patel, MD
Host: Sean Pokorney, MD
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
Host: Manesh R. Patel, MD
Host: Sean Pokorney, MD
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
Host: William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
Guest: Georges Chahoud, MD, FACC, FAHA, FHFSA, FASE
Guest: Patrick J. McCann, MD
Even with guideline-directed medical therapy, or GDMT, many patients with heart failure are limited in their daily activities, due to increasing symptoms and reduced functionality. However, new data from BeAT-HF, a clinical trial that examines the long-term effects of baroreflex activation therapy, or BAT, shows that BAT may provide patients with sustained and durable benefits in exercise capacity, functional status, and quality of life.
Host: Manesh R. Patel, MD
Host: Sean Pokorney, MD
Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.
Host: Tatjana Potpara, MD, PhD, FESC
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Tatjana Potpara, MD, PhD, FESC
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Dennis I. Narcisse, MD, MS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Elaine Hylek, MD, MPH
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: John Alexander, MD, MHS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Geoffrey Barnes, MD, MSc
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Manesh R. Patel, MD
Host: Elaine Hylek, MD, MPH
Host: Renato D. Lopes, MD, MHS, PhD
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Geoffrey Barnes, MD, MSc
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Geoffrey Barnes, MD, MSc
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Manesh R. Patel, MD
Host: Elaine Hylek, MD, MPH
Host: Renato D. Lopes, MD, MHS, PhD
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Dennis I. Narcisse, MD, MS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients at risk of developing blood clots, the treatment of venous thromboembolism (VTE), and the secondary prevention of VTE. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Christopher B. Granger, MD
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Manesh R. Patel, MD
Host: Steve Deitelzweig, MD, MMM, SFHM, FACP, FACC
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: John Alexander, MD, MHS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Steve Deitelzweig, MD, MMM, SFHM, FACP, FACC
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Christopher B. Granger, MD
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Manesh R. Patel, MD
Host: John Alexander, MD, MHS
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Host: Raymond Townsend, MD
Despite many available drug therapies, patients with hypertension continue to experience elevated blood pressures, putting them at risk for cardiovascular-related morbidities and mortality. However, renal denervation, a minimally invasive procedure, has been shown to result in sustained and durable reductions in blood pressure. Find out what this approach could mean for your patients.
Host: Martha Grogan, MD, FACP, FACC
Guest: Marianna Fontana, MD
Guest: Nitasha Sarswat, MD
Once considered rare and untreatable, amyloid transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) has increased in incidence over the last decade and is now a treatable condition. This is partly due to our better understanding of the biology of the disease and recognition of its comorbid or co-occurring conditions in both cardiac and noncardiac patients with cardiac amyloidosis. In an open discussion, chairperson Martha Grogan, MD, and faculty members Marianna Fontana, MD, and Nitasha Sarswat, MD, provide an updated review of the disease state that includes a better understanding of the mechanism of the disease, discuss the pathogenic and protective genetic variants, and examine evidence from clinical trials that are impacting the evolving landscape.
Host: Stefan D. Anker, MD, PhD
Guest: John Cleland, MD
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is a common heart failure comorbidity with a negative impact on patients’ quality of life and mortality. Recent world events may have influenced clinical trial outcomes with IV iron in heart failure, and secondary analysis has become commonplace. Are the findings still clinically relevant, and are we still getting a clinical benefit? Join Drs. Stefan Anker, Piotr Ponikowski, and John Cleland as they differentiate the design of IV iron trials and break down the relevance of key clinical endpoints. Are we still asking the right questions?
Host: M. Cecilia Bahit, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Manesh R. Patel, MD
Host: M. Cecilia Bahit, MD
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Michael J. Cuttica, MD, MS
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
Host: Ruben Mylvaganam, MD
Host: Michael J. Cuttica, MD, MS
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: George Hanna, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Ruben Mylvaganam, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Daniel Schimmel, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Jonathan Haft, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Victor Moles, MD
Host: Jonathan Haft, MD
Host: Daniel Schimmel, MD
Host: Michael J. Cuttica, MD, MS
Host: Thomas Cascino, MD
Host: Ruben Mylvaganam, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Sydney Schacht, DO
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Christopher B. Granger, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Ravi B. Patel, MD, MSc
Host: Vallerie V. McLaughlin, MD
Host: Michael J. Cuttica, MD, MS
Host: Yasmin Raza, MD
Host: Victor Moles, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Manesh R. Patel, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Michael J. Cuttica, MD, MS
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Victor Moles, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Michael J. Cuttica, MD, MS
Host: Victor Moles, MD
Host: Vallerie V. McLaughlin, MD
Host: Ruben Mylvaganam, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Yasmin Raza, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Ravi B. Patel, MD, MSc
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Thomas Cascino, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
Host: Ravi B. Patel, MD, MSc
Host: Thomas Cascino, MD
Host: Yasmin Raza, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
Host: Victor Moles, MD
Host: Michael J. Cuttica, MD, MS
Host: Ravi B. Patel, MD, MSc
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Victor Moles, MD
Host: Michael J. Cuttica, MD, MS
Host: Vallerie V. McLaughlin, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: George L. Bakris, MD, FAHA, FASN
Guest: David Bushinsky, MD
Guest: Lars Lund, MD
Hyperkalemia is a limiting factor when treating patients with heart failure and CKD on RAASi therapy. It’s especially challenging when these patients are on chronic hemodialysis. Join Drs. George Bakris, David Bushinsky, and Lars Lund as they identify the barriers of optimal treatment in patients on hemodialysis and discuss the real-world evidence using potassium-lowering agents in challenging patient group.
Host: Stefan D. Anker, MD, PhD
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is an independent predictor of decreased functional capacity and reduced survival in our patients with heart failure. Multiple clinical trials have addressed the issue, but we continue to struggle with the clinical implications of the data. Join Drs. Stefan Anker, Robert Mentz, and Piotr Ponikowski as they discuss the evidence from IV iron trials in heart failure, past and present, and what the results mean for your practice and patients.
Host: Rajan Saggar, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Adam J. Brownstein, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Christopher B. Cooper, MD, PhD
Host: Alexander Sherman, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Christopher B. Cooper, MD, PhD
Host: Alexander Sherman, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Suzanne Kafaja, MD
Host: Siyuan Cao, MD
Host: Michael Lewis, MD
Host: Rajan Saggar, MD
Host: Shelley Shapiro, MD, PhD
Host: Antoine Hage, MD
Host: Richard N. Channick, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Suzanne Kafaja, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Suzanne Kafaja, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Siyuan Cao, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Rajan Saggar, MD
Host: Houda Boucekkine, MD
Host: Yuri Matusov, MD
Host: Sivagini Ganesh, MD, MPH
Host: Shelley Shapiro, MD, PhD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Houda Boucekkine, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Richard N. Channick, MD
Host: Khushboo Goel, MD
Host: Michael Troy, MD
Host: Sonia Jasuja, MD
Host: Christopher B. Cooper, MD, PhD
Host: Michael Lewis, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Sonia Jasuja, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Michael Troy, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Rajan Saggar, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Richard N. Channick, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Richard Johnson, MD
Guest: Brittany Weber, MD, PhD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: John K. Botson, MD, RPh
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Marco Metra, MD
Guest: Gianluigi Savarese, MD
Clinical trials provide evidence to support guideline recommendations. What’s changed with the recommendations for iron deficiency in heart failure? Watch as experts Giuseppe Rosano, MD, Marco Metra, MD, and Gianluigi Savarese, MD discuss the recent updates to the ESC guidelines, including the latest clinical trial evidence, and the expanded use of IV iron in iron deficient heart failure patients.
Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Guest: Maria Luiza Caramori, MD, PhD, MSc
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
Guest: Pam R. Taub, MD, FACC, FASPC
Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.
Host: Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Guest: Patrick Rossignol, MD, PhD
Heart failure and chronic kidney disease can go hand in hand in your patients, and when they do, there are often added comorbidities such as diabetes. If your patients on RAASi therapy develop hyperkalemia, what should you do? Join Drs. Patrick Rossignol and Antoni Bayés-Genís as they consult on a patient with heart failure who has multiple comorbidities and discuss the impact of hyperkalemia in these complex patients.
Host: Ellie Kelepouris, MD, FACP, FAHA
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with heart failure and chronic kidney disease (CKD) are challenging to manage. The best approach is a multidisciplinary one, which will help to optimize guideline-directed medical therapy in patients at risk for hyperkalemia. Join Drs. Ellie Kelepouris and Stephen Greene as they discuss how to identify patients at high risk of developing hyperkalemia and the available treatment strategies for these complex patients.
Guest: Mazen Hanna, MD
Guest: Marianna Fontana, MD
Once thought to be a rare disease, transthyretin amyloidosis that results in cardiomyopathy (ATTR-CM) remains a challenge to diagnose and treat. In this discussion, Drs. Mazen Hanna and Marianna Fontana provide expert advice on imaging techniques to diagnose ATTR-CM, including recognizing diagnostic “red flags.” They also review recent clinical trial data of current and potential therapeutics for ATTR-CM, so listen in to find out how you can put the evidence into practice.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
Guest: Alan H.B. Wu, PhD
Liver disease patients are at an increased risk of major adverse cardiovascular events (MACE), which is why the doctor in today’s episode believes the multidisciplinary team plays an essential role in managing these patients. Tune in with Dr. Charles Turck as he speaks with Dr. Zobair Younossi, Chair of the Global NASH Council and Professor of Medicine at the Inova Fairfax Medical Campus in Falls Church, Virginia.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Guest: Ovidiu Chioncel, MD, PhD
Guest: Marco Metra, MD
Experts agree intravenous iron treatment for iron-deficient patients with heart failure can improve outcomes, but what are we learning from the recent clinical trials? Drs. Giuseppe Rosano, Marco Metra, Ovidiu Chioncel, and Antoni Bayés-Genís highlight the latest data as they discuss the recent updates to the ESC guidelines and provide expert analysis regarding clinical trials using IV iron. Discover the clinical relevance of the evidence from these trials in patients with heart failure and iron deficiency.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Steve Grinspoon, MD
The risk of cardiovascular disease is twice as great among patients living with HIV, and this could partly be due to traditional risk factors, along with nontraditional risk factors. Here to discuss the results from the REPRIEVE study with Dr. Mary Katherine Cheeley is Dr. Steve Grinspoon, Co-Principal Investigator and Professor of Medicine at Harvard Medical School in Boston.
Host: Nirav Y. Raval, MD, FACC
Guest: Gurusher Panjrath, MD, FACC, FAHA, FHFSA
Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Brian Howard and William Abraham explore data on its positive effects on exercise capacity, functional status, and quality of life. Do you know which of your patients may benefit from BAT?
Host: Jennifer Caudle, DO
Guest: Chantal Tinfang, MD
Guest: Kesha Love, MSN, RN
The AMA MAP™ Hypertension program is designed to enable physicians and care teams to achieve rapid and sustained improvements in blood pressure control among their patients with hypertension. In the fall of 2020, Cook County Health, which is one of the largest public health systems in the country based in Chicago, collaborated with the AMA to implement this program, and here to share the results with Dr. Jennifer Caudle are Dr. Chantal Tinfang and Ms. Kesha Love. Dr. Tinfang is an attending physician of family medicine at Provident Hospital at Cook County Sengstacke Primary Care Clinic, and Ms. Love is a registered nurse and Director of Health Information Technology Interoperability Services at Cook County Health. The AMA MAP™ Hypertension program and all components are not intended to diagnose or treat disease or other conditions. AMA MAP™ Hypertension program and all components are not medical devices and have not been evaluated by the Food and Drug Administration. Information provided through the AMA MAP™ Hypertension program and all components is not intended to direct or substitute for the independent assessment or judgment of a qualified health care professional.
Host: Tessa Laubscher, MBChB, CCFP, FCFP
Guest: George L. Bakris, MD, FAHA, FASN
Guest: Mikhail Kosiborod, MD
Managing chronic kidney disease (CKD) and type 2 diabetes (T2D) with multiple medications has become a challenge, and a multidisciplinary approach is needed to achieve optimal cardiorenal outcomes. Join Drs. George Bakris, Mikhail Kosiborod, and Tessa Laubscher as they discuss initiating consensus-based nonsteroidal MRA therapy in their patients with CKD and T2D.
Host: Piotr Ponikowski, MD, PhD, FESC, FHFA
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
While multiple clinical trials demonstrated a positive impact on patient outcomes with IV iron therapy in patients with HFrEF and iron deficiency, few have addressed the long-term effects of IV iron treatment on morbidity, mortality, and exercise tolerance in these patients. Join Dr. Robert Mentz and Dr. Piotr Ponikowski as they discuss the design of the HEART-FID trial and its potential impact on the clinical applications of long-term treatment with IV iron products in patients with heart failure and iron deficiency.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA
The National Lipid Association (NLA) recently published updated recommendations for lifestyle therapies to manage three common dyslipidemias in adults. To discuss this, Dr. Mary Katherine Cheeley is joined by Dr. Carol Kirkpatrick, Clinical Lipid Specialist and Clinical Scientist at Midwest Biomedical Research.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Steve Grinspoon, MD
Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and Dr. Steven Grinspoon, Professor of Medicine at Harvard Medical School and Chief of the Metabolism Unit at Massachusetts General Hospital.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Patrick Rossignol, MD, PhD
With more effective ways to manage hyperkalemia, is it still a challenge in 2023? Chairperson Ileana Piña, MD, and faculty members cardiologist Javed Butler, MD, and nephrologist Patrick Rossignol, MD, use case-based vignettes to provide expert analysis regarding hyperkalemia in patients with HFrEF who are on RAASi therapy. Tune in for insights on applying clinical trial data to the unique challenges of complex cases and learn how a guideline-based approach, innovative treatments, and emerging data are achieving successful outcomes in patients with heart failure with hyperkalemia.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Maya S. Safarova, MD, PhD, FNLA
Learn which patients with low-density lipoprotein (LDL) would benefit from this group of medication. In this episode, Dr. Alan Brown is joined by Dr. Maya Safarova, Chief Fellow in the Department of Cardiovascular Medicine at the University of Kansas Medical Center, to discuss the benefits of non-statin LDL lowering therapies.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Alan S. Brown, MD, FACC, FAHA, FNLA
Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host, Dr. Alan Brown, Past President of the National Lipid Association.
Guest: Santica Marcovina, PhD, ScD
Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out.
Sponsored by Novartis Pharmaceuticals Corporation.
6/23 278623
It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis.
Sponsored by Novartis Pharmaceuticals Corporation.
6/23 278623
Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis.
Sponsored by Novartis Pharmaceuticals Corporation.
6/23 278623
Host: Vallerie V. McLaughlin, MD
Guest: Rajan Saggar, MD
Diagnosis of pulmonary arterial hypertension, or PAH, may be delayed because symptoms are nonspecific. And while there have been many advances in terms of available treatments, it remains imperative that providers perform a thorough risk assessment on each patient. In addition, it’s necessary to develop both a multidimensional approach to caring for patients with PAH and a communication plan to use with patients, care partners, and caregivers. If we can improve how we practice, we can improve outcomes and quality of life. Join us!
Host: Richard Krasuski, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
Guest: Richard Krasuski, MD
Guest: Dinesh Khanna, MD, MS
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Richard Krasuski, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Richard Krasuski, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
Guest: Jean M. Elwing, MD
Guest: Martha Kingman, FNP-C, DNP
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Richard N. Channick, MD
Guest: Dinesh Khanna, MD, MS
Guest: Rajan Saggar, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Dinesh Khanna, MD, MS
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Dinesh Khanna, MD, MS
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Dinesh Khanna, MD, MS
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Sudarshan Rajagopal, MD, PhD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Oksana A. Shlobin, MD
Guest: Rajan Saggar, MD
Guest: Sudarshan Rajagopal, MD, PhD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Javed Butler, MD, MBA, MPH
Guest: John W. MacArthur
With many barriers standing in the way of people in the United States who need a heart transplant, fewer than 10 percent of patients actually receive this life-saving surgery according to Stanford Medicine. Therefore, surgeons are working on different techniques to increase the pool of healthy donated hearts. To speak more about this, Dr. Javed Butler is joined by Dr. John MacArthur, Assistant Professor of Cardiothoracic Surgery at Stanford School of Medicine.
Host: John Buse, MD, PhD
Guest: Steven Nissen, MD
Among statin-intolerant patients, treatment with bempedoic acid is associated with a lower risk of major adverse cardiovascular events according to a recent study. Dive into the study’s key findings with Dr. John Buse and Dr. Steven Nissen, who published the placebo-controlled study of bempedoic acid among statin-intolerant patients in The New England Journal.
Host: Javed Butler, MD, MBA, MPH
Guest: John P. Boehmer, MD
Heart failure contributes to more than 3 million hospital admissions, resulting in a considerable economic burden. Despite significant developments to advance treatment, hospital readmission rates also remain high. Join Drs. Javed Butler and John Boehmer as they discuss fluid overload in patients with heart failure and explore recent clinical evidence in remote monitoring strategies to improve patient outcomes.
Host: Robert Hegele MD, FRCPC
Guest: Stephen Nicholls, FRACP, FACC, FESC, FAHA
Coronary atherosclerosis is a chronic condition that can start early in life, and plaques gradually and progressively accumulate in the walls of arteries over decades. Plaques are diverse, and there are quantitative and qualitative aspects of the plaque. And it’s these qualitative aspects that make a plaque more vulnerable. So what are the key features and impacts of a vulnerable plaque, and what are the imaging modalities that can be used to look at changes in plaque burden and composition? Find out the answers to these and other key questions with Dr. Robert Hegele from Western University and Professor Stephen Nicholls from Monash University. ©2023 Amgen Inc. All rights reserved. USA-145-84521 3/23
Guest: Patricia A. Pellikka, M.D.
Artificial intelligence (AI) has several applications in cardiology, such as echocardiography. Can machine learning and AI algorithms in echocardiology help clinicians better detect heart failure with preserved ejection fraction (HFpEF)? Dr. Patricia A. Pellikka, Director of the Ultrasound Research Center at the Mayo Clinic, shares data from ACC.23 and explores the potential of AI in detecting HFpEF.
Guest: Paul Sorajja, MD
TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its results may lead to significant improvements in care and quality of life. To learn more about this trial, Dr. Paul Sorajja from the Minneapolis Heart Institute Foundation details the key findings from this trial and explores their impact.
Host: John Buse, MD, PhD
Guest: Jennifer B. Green, MD
The COORDINATE Study evaluated patients with cardiovascular disease and type 2 diabetes who encounter barriers in receiving newer diabetes medications. To better understand these gaps in care, Dr. John Buse speaks with one of the researchers, Dr. Jennifer Green from Duke University in Durham, North Carolina.
Host: Marius M. Hoeper
A recent study explored the safety and efficacy of sotatercept on top of background pulmonary arterial hypertension (PAH) therapy. To learn more about this clinical data, Dr. Marius M. Hoeper, a Professor of Medicine and the Deputy Director of the Department of Respiratory Medicine at Hannover Medical School in Hannover, Germany, dives into the results of this trial and explores how they may impact patients with PAH.
Host: Javed Butler, MD, MBA, MPH
Guest: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, there is a propensity to down-titrate or discontinue guideline-directed medical therapy in the presence of hyperkalemia, even though it is well known that suboptimal use of these therapies leads to poorer outcomes for our patients with heart failure and chronic kidney disease. Join Drs. Javed Butler, Ileana Piña, and Patrick Rossignol as they take a multidisciplinary approach to a patient case and discuss dosing and other treatment decisions.
According to the CDC, patients with familial hypercholesterolemia or patients who show signs of coronary heart disease are at an increased chance of having heart attack, stroke, and aortic stenosis due to high levels of lipoprotein(a). So how can me manage lipoprotein(a) in our patients? To discuss this, Dr. Mary Katherine Cheeley is joined by fellow ReachMD host Dr. Alan Brown, who’s also the Director of the Division of Cardiology and the Lipid Clinic at Advocate Lutheran General Hospital.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Kevin C. Maki, PhD, FNLA, CLS
At the American College of Cardiology's 72nd Annual Scientific Session & Expo, cardiologists will gather to explore the latest advancements in the field. Joining us to share what you can expect to learn about statin intolerance at their upcoming session are Dr. Mary Katherine Cheeley and Dr. Kevin Maki.
Host: Adam DeVore, MD
Guest: Lauren Barron, MD
Guest: Navin Kapur, MD
Less than 20% of patients admitted to the hospital with new-onset heart failure are assessed for coronary artery disease (CAD) even though revascularization can improve survival. Many transplant patients go without a CAD assessment or intervention at earlier stages, but treatment could slow progression of their heart failure or even reverse it. Join Drs. Adam DeVore, Lauren Barron, and Navin Kapur as they discuss the gaps in care with CAD and how you can take action to improve your patients’ outcomes.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Laney K. Jones, PharmD, MPH
Patients with familial hypercholesterolemia (FH) are at an increased risk of developing coronary heart disease at a young age. So what’s on the horizon for using implementation science strategies in treating patients with FH? Learn more about implementation science as Dr. Mary Katherine Cheeley discusses this with Dr. Laney Jones, Associate Professor at Geisinger’s Department of Genomic Health.
Host: Javed Butler, MD, MBA, MPH
Guest: Stefan D. Anker, MD, PhD
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Symptoms from iron deficiency can greatly affect the overall quality of life of our patients with heart failure. Recent clinical evidence from the IRONMAN trial explores the use of IV iron replacement in patients with chronic heart failure. Join Drs. Javed Butler, Stefan Anker, Piotr Ponikowski, and Robert Mentz as they discuss the clinical trial design and outcomes from IRONMAN compared to the current body of evidence for managing iron deficiency in this setting.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Lauren Williams, MCN,RD,LD
Kids with dyslipidemia don’t have much different nutritional needs than other young kids their age. However, there are a few key things to be aware of. So how can clinicians meet families where they are to improve their diet? Dive into the unique needs of youth with dyslipidemia as Dr. Mary Katherine Cheeley is joined by Lauren Williams, Class II Clinical Dietician at Cook Children’s Health System.
Host: Matthew Sorrentino, MD
Guest: Luke Laffin, MD
Six commonly used supplements thought to improve patients’ cholesterol may be doing more harm than good. So what do we need to know about these supplements? To walk us through the results of the SPORT trial, Dr. Matthew Sorrentino is joined by Dr. Luke Laffin, Co-Director of the Center for Blood Pressure Disorders at the Cleveland Clinic.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Kamyar Kalantar‐Zadeh, MD
Guest: Pieter Martens, MD, PhD
Patients with heart failure are at increased risk for iron deficiency which leads to poor outcomes and quality of life. Several intravenous iron formulations are available to clinicians, yet iron deficiency remains undertreated. Join Dr. Giuseppe Rosano, Dr. Pieter Martens, and Dr. Kamyar Kalantar-Zadeh as they discuss differing iron formulations and the current body of evidence for managing iron deficiency in patients with heart failure.
Host: Marat Fudim, MD, MHS
Despite the use of guideline-directed medical therapy (GDMT), many heart failure (HF) patients may experience worsening symptoms and disease progression. There is now an FDA-approved device that works with GDMT and uses the baroreflex to improve HF-related physiological effects and clinical consequences. Tune in to keep up with baroreflex activation therapy, its mechanism of action, and the associated improved patient outcomes.
Host: Javed Butler, MD, MBA, MPH
Guest: Scott Solomon, MD
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER trial) is a study designed to assess the effectiveness of SGLT2 inhibitors in patients with higher left ventricular ejection fraction. To help lead the discussion on the results of this study, Dr. Javed Butler is joined by Dr. Scott Solomon, lead study author and Director of the Clinical Trials Outcomes Center and the Edward D. Frohlich Distinguished Chair at Harvard Medical School.
Host: Javed Butler, MD, MBA, MPH
Guest: William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
Cardiac contractility modulation (CCM) is a novel, approved, implantable device that significantly improves heart failure symptoms, exercise tolerance, and quality of life while reducing the rate of heart failure hospitalizations. Find out why you should consider sending your patients with NYHA Class III heart failure who are not responding to guideline-directed medical therapy directly to an electrophysiologist for device implantation.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Piotr Ponikowski, MD, PHD, FESC, FHFA
Guest: Adrian F. Hernandez, MD, MHS
Guest: Professor Andrew Sindone
Despite being an important and common comorbid condition in patients with heart failure, iron deficiency remains underdiagnosed and undertreated. Join Dr. Piotr Ponikowski, Dr. Andrew Sindone, and Dr. Adrian Hernandez as they discuss using guideline-directed medical therapy to overcome the morbidity, mortality, and very poor quality of life experienced by patients with heart failure and iron deficiency.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency in patients with heart failure remains underdiagnosed, undertreated, and commonly overlooked in non-anemic patients and has a significant impact on patient outcomes and quality of life. Join Dr. Robert Mentz and Dr. Peter van der Meer as they discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.
Host: Suzanne J. Baron, MD
Guest: Jonathan A. Bradlow, MD, FACC
Guest: Kendra J. Grubb, MD
Data are limited on the incidence and factors associated with structural valve deterioration (SVD) after transcatheter aortic valve replacement (TAVR) and surgery for severe aortic stenosis in patients of all risk levels. The lifetime management of these patients requires an understanding of bioprosthetic valve durability and failure. Tune in for new evidence evaluating the 5-year incidence, outcomes, and predictors of hemodynamic SVD in patients undergoing TAVR and surgery that will support best practices for treatment selection.
Host: Charles P. Vega, MD
Guest: Rajeev Raghavan, MD, M.Ed, FASN
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.
Host: Marco Metra, MD
Guest: Piotr Ponikowski, MD, PHD, FESC, FHFA
Iron deficiency, independent of anemia status, is common in heart failure and is associated with increased risk for heart failure hospitalization and cardiovascular mortality, reduced functional status, and poor exercise performance. This impact may be magnified in patients with ischemic etiology. Join Dr. Marco Metra and Dr. Piotr Ponikowski as they discuss the clinical relevance of ischemic etiology in the management and outcomes of patients with heart failure and iron deficiency.
Host: Mikhail Kosiborod, MD
Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.
Host: John J. Russell, MD
Guest: Vallerie V. Mclaughlin, MD
Join Dr. John Russell as he speaks about diagnosing and treating pulmonary arterial hypertension using the latest pharmacologic and medical management strategies with Dr. Valerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan.
Host: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Javier Morales, MD, FACP, FACE
Guest: Angela Yee-Moon Wang, MD, FACP, FACE
Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) and is associated with mortality and morbidity worldwide. Recent data on the use of nonsteroidal MRAs were presented at the European Society of Cardiology and other major meetings and were simultaneously published in major journals. Join our experts to explore these data and find out how you can better prevent the deterioration of renal function and improve cardiovascular outcomes in your patients across the spectrum of renal decline.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Nanette F. Santoro, MD
Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.
Host: Dixon W. Wilde, PhD, FAHA
Guest: Vallerie V. Mclaughlin, MD
In the management of the pulmonary arterial hypertension (PAH) patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, based on the registries, from which the modern risk assessment models have been developed, it’s clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there’s a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy and lung transplantation.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Adrian F. Hernandez, MD, MHS
Recent clinical trial data and subsequent approval of novel therapies have expanded the treatment armamentarium. These advances have the potential to improve long-term patient outcomes, but also make the choice of therapy more complex. This activity aims to educate clinicians managing patients with HFrEF already on guideline-directed medical therapy (GDMT) who continue to be at high risk of rehospitalization to recognize the clinical characteristics of worsening heart failure and to select appropriate HF treatment strategies including novel classes of agents in heart failure.
Host: Javed Butler, MD, MBA, MPH
Guest: Pam R. Taub, MD, FACC, FASPC
Guest: Marc S. Sabatine, MD, MPH
Two lipid experts will 1) provide an overview of the landscape of nonstatin, LDL-C-lowering therapy, 2) explain current guideline recommendations, 3) describe the evidence with ezetimibe and PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), 4) discuss cardiovascular risk reduction with PCSK9 inhibitors in a variety of very high risk ASCVD patient populations, and 5) emphasize the need to incorporate PCSK9 inhibition early in acute coronary syndrome patients to facilitate best patient outcomes.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Zachary Marcum, PharmD, PhD
Hypertension affects nearly half of adults in the United States and is associated with cognitive decline and dementia. A wide variety of antihypertensive medications are prescribed to millions of people to control blood pressure and prevent vascular dementia. Could it be that certain medications are better than others in preventing brain injury from chronic hypertension? Dr. Andrew Wilner is joined by Dr. Zachary Marcum, Associate Professor in the School of Pharmacy-University of Washington, to discuss his recent study investigating the association between certain hypertension medications and reduced cognitive impairment.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A pragmatic approach that addresses residual cardiovascular (CV) risk across a variety of risk factors and that goes beyond LDL-C lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients require review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: Javed Butler, MD, MBA, MPH
Guest: Justin Ezekowitz, MD, MBBCh, MSc
The Study of Dietary Intervention under 100 millimole in Heart Failure (SODIUM-HF) trial was designed to assess the effects of a low-sodium diet on adverse cardiovascular events. So what were the study’s findings, and what do they mean for our patients with heart failure? Dr. Javed Butler is joined by Dr. Justin Ezekowitz, who shared the SODIUM-HF trial results at the 2022 American of Cardiology Annual Scientific Meeting.
Host: Marco Metra, MD
Guest: Adrian F. Hernandez, MD, MHS
Since the 2017 AHA/ACC/HFSA guidelines, considerable research has been conducted in the care of patients with heart failure, including the impact of iron deficiency. The new 2022 guidelines have considerable updates based on the totality of current evidence. Join Dr. Adrian Hernandez and Dr. Marco Metra as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.
Host: Mikhail Kosiborod, MD
Guest: Michael Böhm, MD, FESC
The 2022 updates to the ACC/AHA guidelines for heart failure are the first since 2017. In the interim, considerable research has been conducted on the impact of optimal RAASi therapy and the management of hyperkalemia in patients with heart failure. Join Dr. Mikhail Kosiborod and Dr. Michael Böhm as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Christie M. Ballantyne, MD
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Joseph Saseen, PharmD, BCPS, BCACP, CLS
Guest: Karol Watson, MD, PhD
Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.
Host: Javed Butler, MD, MBA, MPH
Guest: John Cleland, MD
Guest: Fraser Graham, MD
Iron deficiency is one of the most frequent comorbidities in patients with heart failure and is estimated to present in up to 50 percent of patients. So what’s the criteria for iron deficiency, and how is it currently defined in cardiology? To discuss this, Dr. Javed Butler is joined by Drs. John Cleland and Fraser Graham from the Institute of Health and Wellbeing at the University of Glasgow.
Host: Ahmad Masri, MD, MS
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
—Breaking News—Commentary on HCM-related Late-Breaking Abstracts presented at ACC.22 in April has been added to the start of the program. The rest of the program will cover the following topics: Why do we need new therapies in hypertrophic cardiomyopathy (HCM), and will newer and emerging cardiac myosin inhibitors improve the standard of care for patients with HCM? What differences can we expect regarding patient outcomes and quality of life with these new therapies? Join Dr. Ahmad Masri and Dr. Deepak Bhatt as they explore how newer cardiac myosin inhibitors go beyond traditional medical management (that only addresses the macro-pathophysiology and disease symptoms) to actually treat HCM at the cellular level.
Host: Javed Butler, MD, MBA, MPH
Guest: Mikhail Kosiborod, MD
With the prevalence of heart failure continuing to rise worldwide, recent trials have shown that sodium glucose co-transporter 2 (SGLT2) inhibitors may improve impairments and decrease the risk of hospitalizations. So based on these recent findings, what exactly is their role in the management of patients with heart failure? Find out with Dr. Javed Butler as he speaks with Dr. Mikhail Kosiborod, Professor of Medicine at the University of Missouri-Kansas City and Vice-President of Research at Saint Luke's Health System.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan D. Rich, MD
Guest: Paul Doghramji, MD
According to recent data, more than 50 percent of patients with heart failure with preserved ejection fraction (HFpEF) are hospitalized. Given that troubling statistic, how can we as clinicians work together to reduce the risk of hospitalization among patients with HFpEF? Joining Dr. Charles Turck to share their multidisciplinary perspectives on this important topic are cardiologist Dr. Jonathan Rich and primary care provider Dr. Paul Doghramji.
Host: Mikhail Kosiborod, MD
Guest: Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
RAASi therapy is a critical component of heart failure management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. This is especially evident in our patients with chronic kidney disease. So how can we simultaneously maintain optimal therapy and manage hyperkalemia? Join Dr. Mikhail Kosiborod and Dr. Austin Stack as they discuss a patient case and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: Ahmad Masri, MD, MS
Guest: Steve R. Ommen, MD
What if a patient has fatigue, dyspnea, chest pain, palpitations, presyncope, left ventricular afterload, and diastolic dysfunction? Is it heart failure? Is it left ventricular hypertrophy due to arterial hypertension? Is it aortic stenosis? Did you even consider hypertrophic cardiomyopathy? Join Dr. Ahmad Masri and Dr. Steve Ommen as they discuss the challenges of HCM diagnosis and why you should get to know HCM!
Host: Hector O. Chapa, MD, FACOG
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: Anum Minhas, MD, MHS
Cardiovascular disease is currently the leading cause of death for pregnant and postpartum women in the United States, and from a global perspective, hypertensive complications during pregnancy result in 50,000 maternal deaths each and every year. This, along with the increasing rates of peripartum cardiomyopathy diagnoses, is why a new subspeciality of cardiology is needed. So what exactly is cardio-obstetrics? To learn more about how this emerging subspecialty is helping to provide better care for our pregnant and postpartum patients, Dr. Hector Chapa speaks with Drs. Erin Michos and Anum Minhas.
Host: Matthew Sorrentino, MD
Guest: Javed Butler, MD, MBA, MPH
In a groundbreaking procedure, a 57-year-old man with life-threatening heart disease received a heart from a genetically altered pig. Surgeons at the University of Maryland Medical Center performed the 8-hour operation, making it the first successful transplant of a pig's heart into a human being. And while much is still uncertain, what could this achievement mean for the future of organ transplantation? That’s what ReachMD hosts Dr. Matthew Sorrentino and Dr. Javed Butler explore together.
Please note: Since the date of publication, David Bennet, the patient who received a heart transplant from a pig, died at the age of 57 at the University of Maryland Medical Center on March 8, 2022.
Host: Eugene E. Wright, Jr., MD
Guest: Jolanta Małyszko, MD, PhD
Guest: María José Soler, MD, PhD
Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.
Host: Javed Butler, MD, MBA, MPH
Guest: Stefan D. Anker, MD, PhD
The DIAMOND trial recently released topline results, adding to the growing clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. So what do the data mean for our patients? Join Dr. Stefan Anker and Dr. Javed Butler as they discuss the value of these results and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: Javed Butler, MD, MBA, MPH
Guest: Shelley Zieroth, MD
Have you started using newly approved therapies when caring for your patients with heart failure with reduced ejection fraction (HFrEF)? Tune in to hear Drs. Javed Butler and Shelley Zieroth discuss strategies you can use to determine the best treatment approaches for your most challenging patients. A 3D mechanism of action animation is included to help you understand the workings of novel classes of agents in heart failure. Make sure you get with the guidelines, because guideline-directed medical therapy really does work.
Host: Matt Birnholz, MD
Guest: Andrew Wang, MD
Although hypertrophic cardiomyopathy is the most common inherited heart disease, it is estimated that many patients remain undiagnosed. But why is that, what are the steps to help close the diagnostic gap, and what are the current management approaches for HCM? Joining Dr. Matt Birnholz to answer these questions and more is Dr. Andrew Wang, Vice Chief for Clinical Affairs for Duke University's Division of Cardiology and Director of the Duke Hypertrophic Cardiomyopathy Clinic.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Joseph Marek, MD
Sudden cardiac death is rare in younger patients, but it remains one of the leading causes of death in young athletes. To learn more about this, Dr. Alan Brown is joined by Dr. Joseph Marek, Clinical Cardiologist and Senior Medical Director of Cardiopulmonary Service at Advocate Medical Group, to share how his foundation, Young Hearts 4 Life, is working to increase awareness for sudden cardiac arrest and provide young athletes resources.
Host: Peter Rossing, DMSc, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Matthew R. Weir, MD
Achieving optimal outcomes in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remains a challenge, and treating physicians need to embrace multidisciplinary components when managing progression to CKD.
In this discussion, Drs. Gerasimos Filippatos, Peter Rossing, and Matthew Weir review the unmet needs of patients with CKD and T2D. They also explore the role of mineralocorticoid receptor antagonists (MRAs) in the treatment spectrum and review recent findings from clinical trials. Tune in to ensure you’re doing all you can for each of your patients.
Host: Javed Butler, MD, MBA, MPH
Guest: Faiez Zannad, MD, PhD
What do we need to know about the relationship between heart failure and ejection fraction? Dr. Javed Butler is joined by Dr. Faiez Zannad, Emeritus Professor of Cardiology at Université of Lorraine, to discuss current updates in ejection fraction and share what we need to know.
Host: Murray Epstein, MD
Guest: Gates B. Colbert, MD, FASN
Determining the optimal strategies for treating patients with chronic kidney disease (CKD) can be challenging. After decades of waiting, exciting and rapid progress in renin-angiotensin-aldosterone system (RAAS) inhibition is being made, but these therapies can lead to hyperkalemia. The trick is to sustain optimal therapy in the patient without interruption or reduction. Are you familiar with novel potassium binders and recent changes in guideline-directed medical therapy surrounding their use? Tune in because these resources are offering new therapeutic opportunities for your patients with CKD.
Join Drs. Murray Epstein and Gates Colbert to ensure you’re up to date on the latest treatment options for your patients with CKD.
Host: Lisa K Moores, MD, FCCP, MACP
Guest: David Jiménez MD, PhD, FERS
Guest: Geert-Jan Geersing MD, PhD
Physicians are challenged in adopting the latest clinical guidelines and integrating new and existing treatment advances into practice when managing patients with VTE.
Host: Peter van der Meer, MD, PhD
Guest: Pieter Martens, MD, PhD
Iron deficiency (ID), independent of anemia status, is common in heart failure with reduced ejection fraction (HFrEF). In normal cardiac physiology, contractility increases disproportionally to heart rate; however, in HFrEF and concomitant ID, this response is impaired. Additionally, HFrEF patients with ID who receive cardiac resynchronization therapy (CRT) exhibit diminished cardiac reverse remodeling after CRT implant.
In this discussion, Drs. Martens and van der Meer discuss how physicians can work to improve reverse cardiac remodeling, the force-frequency relationship, and quality of life in patients with HFrEF and ID receiving CRT.
Host: George L. Bakris, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Hyperkalemia is common in chronic heart failure and is associated with an increased risk of hospitalization and death. The incidence is further elevated in those with chronic kidney disease, and the presence of hyperkalemia can often lead to clinical delay and suboptimal dosing of RAAS inhibitors in these patients.
Join the discussion as Drs. George Bakris and Giuseppe Rosano examine the management of hyperkalemia in patients with HF and provide individualized approaches for optimizing RAASi therapy. Collaboration between nephrologists and cardiologists is key, and these experts make sure to stress the strong connection between the heart and kidneys when managing these patients.
Guest: Richard Channick, MD
Guest: Vallerie V. Mclaughlin, MD
It can be very challenging to differentiate between WHO Class 1 Pulmonary Arterial Hypertension and WHO Class 3 Pulmonary Hypertension due to Lung Disease or Chronic Hypoxia. Despite similar clinical manifestations, these two conditions are characterized by different hemodynamic definitions and etiologies. Through the use of 2 case studies, clinicians can learn about the diagnosis and management of PAH versus PH due to lung disease or chronic hypoxia.
Host: Lisa Baumann Kreuziger, MD, MS
Guest: Marc Carrier MD, FRCPC
Guest: Rachel P. Rosovsky, MD, MPH
Although evidence corroborates the safety and efficacy of managing low-risk patients with VTE in outpatient settings through prophylactic extension, the majority of this subtype is still being treated in hospital settings.
Host: Stavros Konstantinides, MD, FRCP (Glasg)
Guest: Riyaz Bashir MD, FACC
Guest: Akhilesh Sista, MD, FSIR, FAHA
High risk patients and those with identifiable symptoms are not routinely receiving prophylaxis treatment that could prevent the development of VTE.
Guest: Norman E. Lepor, MD
Tune in to hear Dr. Norman Lepor from the UCLA Geffen School of Medicine discuss the role of LDL-C and comorbidities in atherosclerotic cardiovascular disease (ASCVD) risk assessment as well as the limitations of statin treatment.
10/21 121913
Host: Peter Libby, MD
Guest: Lawrence A. Leiter, MD
Guest: Prof. Kausik Ray, MBChB, MD, MPhil
This CME Roundtable highlights key takeaways and late-breaking data shared at a symposium held at the AHA annual meeting. Hear updated management strategies, new data, and guidelines to help you manage patients with established ASCVD who are at an increased risk of myocardial infarction, stroke, and death.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Maryam Lustberg, MD, MPH
Can cardiac rehabilitation programs play a role in the management of breast cancer survivors? Dr. Maryam Lustberg, Chief of Breast Medical Oncology and the Director of The Breast Cancer Center at Smilow Yale Cancer Center, shares the common risk factors between cardiovascular disease and cancer and why these types of programs are beneficial to patient care.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Marco Metra, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
In the management of patients with heart failure, foundational therapy is critical to improving patient outcomes. Are you up to date on the latest recommendations concerning MRAs, ACEI/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors? Recent updates to the ESC/HFA guidelines, heart failure clinical trials, and the COVID-19 pandemic have impacted the way we manage our patients, so tune in to keep up with the latest developments.
Our experts, Drs. Ileana Piña, Javed Butler, Marco Metra, and Giuseppe Rosano, discuss the ESC/HFA guideline updates and how these changes impact the clinical considerations for managing recurrent hyperkalemia and the recommended foundational therapy for patients with heart failure.
Host: Mikhail Kosiborod, MD
Guest: Javed Butler, MD, MBA, MPH
Guest: Matthew R. Weir, MD
Renin-angiotensin-aldosterone system inhibition (RAASi) is the foundation of guideline-directed medical therapy (GDMT) for heart failure patients. However, due to practice gaps, a significant proportion of the population requiring its use do not experience the benefits of RAASi therapy, which is especially true for patients with comorbid conditions. Hyperkalemia is a common adverse effect of RAASi therapy that needs to be anticipated and mediated so that the optimal dosing of necessary medications can occur. Maximizing GDMT in the face of hyperkalemia remains a key clinical challenge that, if not handled properly, can result in increased morbidity and mortality.
In this activity, Drs. Javed Butler, Mikhail Kosiborod, and Matthew Weir review a patient case and discuss different treatment approaches to optimize GDMT while managing hyperkalemia. Tune in to make sure you’re doing all you can to improve outcomes for your patients with heart failure and comorbid conditions.
Host: Javed Butler, MD, MBA, MPH
Guest: Ileana L. Piña, MD, MPH, FAHA, FACC
Not all patient subgroups respond to medication the same way, making equal representation in clinical trials essential. Dr. Javed Butler is joined by Dr. Ileana Piña, a Heart Failure Cardiologist and Clinical Professor of Medicine at Central Michigan University, to talk about how we can improve diversity in cardiovascular clinical trials.
Host: Javed Butler, MD, MBA, MPH
Guest: Piotr Ponikowski, MD, PHD, FESC, FHFA
In this video, Drs. Javed Butler and Piotr Ponikowski discuss the clinical significance of iron deficiency in patients suffering from heart failure with reduced ejection fraction. They also take a close look at the key updates to the 2021 ESC/HFA guidelines. Tune in to stay up to date with the latest recommendations.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Leslie Cooper, Jr., MD
Can COVID-19—along with its vaccines—impact the heart? Dr. Charles Turck is joined by Dr. Leslie Cooper, a myocarditis expert and chair of the Department of Cardiovascular Diseases at Mayo Clinic in Florida, to investigate the cardiac impacts of COVID-19 and the COVID-19 vaccines. For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org.
Host: Gregg C. Fonarow, MD
Guest: Andrew J. S. Coats, MD
Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.
In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.
Host: Keith C. Ferdinand, MD
Guest: Marco Metra, MD
There is a substantial gap between the guideline recommendations for treatment and the real-world prescribing patterns of RAASi therapy. This disconnect results in worse cardiorenal outcomes and higher mortality in patients receiving suboptimal dosing. This is particularly true in patients with CKD who develop hyperkalemia, which constitutes the major barrier to optimal therapy.
In this activity, Drs. Ferdinand and Metra discuss how best to manage comorbidities, optimize RAASi therapy, and improve the long-term care for our patients with heart failure.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Sheng Xu, PhD
Sheng Xu, Professor of Nanoengineering, Bioengineering, Computer and Electrical Engineering at the UC San Diego Jacobs School of Engineering, meets with Dr. Alan Brown to discuss his innovative technology to change the way we predict cardiovascular risks.
Guest: Muthiah Vaduganathan, MD, MPH
What do we currently know about the cardiac consequences of the COVID-19 vaccines? Dr. Muthiah Vaduganathan, cardiologist and investigator at Brigham Women's Hospital at Harvard Medical School, addresses the cardiac concerns surrounding the vaccines and how we can talk to patients about them.
Host: Mikhail Kosiborod, MD
Guest: Ewa A. Jankowska, MD, PhD, FESC
Guest: Phil McEwan, PhD
Assessing iron deficiency is a crucial aspect of heart failure (HF) that warrants close clinical consideration, especially because it remains underdiagnosed and undertreated.
In this expert panel discussion, we examine data from AFFIRM-HF supporting the importance of correcting iron deficiency in patients with HF. Find out how treating iron deficiency can change the natural history of heart disease, lead to cost savings, and improve patients’ lives.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Rapid initiation and up-titration of guideline-directed medical therapy (GDMT) is critical to achieve optimal patient outcomes in heart failure. This is particularly important in patients with multiple comorbidities and in pivotal situations to avoid stopping or lowering the dose of any of the four critical medicines that these patients must receive.
Drs. Javed Butler, Ileana Piña, and Giuseppe Rosano will recap the data and the views that were presented at a symposium held in conjunction with the Heart Failure Society of America’s 2021 annual scientific meeting.
Host: Robert J. Chilton, DO
Guest: John R. Nelson, MD, FACC, FNLA, FASNC
Join Drs. Chilton and Nelson as they discuss recent omega-3 fatty acid (OM-3) outcomes trial results and how to apply those results along with evidence-based guidelines to reduce ASCVD risk. Tune in to hear about the use of OM-3s including dietary supplement OM-3s that are readily available in pharmacies and online, so you can keep your patients informed!
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Stuart H. Isaacson, MD
Guest: Salima Brillman, MD
Guest: Sean C. Beinart, MD
Join Dr. Stuart Isaacson, a neurologist and movement disorder specialist, as he welcomes fellow neurologist and movement disorder specialist Dr. Salima Brillman and cardiologist Dr. Sean Beinart to discuss neurogenic orthostatic hypotension (nOH) causes, symptomatology, disease burden, and approaches to optimal management involving collaboration between neurology and cardiology specialists.
During their discussion, the following questions will be addressed:
- What is nOH and how is it diagnosed?
- What leads to symptoms of nOH?
- What are some common and less common symptoms of nOH?
- What is the impact of nOH symptoms on the patient and the caregiver?
- How do we approach the management of nOH symptoms?
- How can cardiologists and neurologists collaborate in managing patients with nOH?
For additional reference please review: Cutsforth-Gregory JK, Low PA. Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer. Neurol Ther. 2019 Dec;8(2):307-324.
© 2021 Lundbeck. All rights reserved. UBR-D-100900
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Gregg C. Fonarow, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Recent guideline updates and publications are leading to changes in care in patients with heart failure with reduced ejection fraction (HFrEF). What clinical evidence is driving recent changes to guideline directed medical therapy (GDMT) in HFrEF, and what real-world data exists that may impact the landscape of care and patient outcomes?
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have not only disrupted the regular care of patients with heart failure, but also clinical trials and their participation rates.
These studies are critical for determining the safety and efficacy of new drugs and innovative treatments. When the pandemic started, some clinical trials shut down permanently while others are finally, albeit slowly, resuming. This has created a delay in the research pipeline that may hinder how quickly new heart failure medications come to market in the next few years.
Join us as our experts—Drs. Deepak Bhatt, Javed Butler, and Giuseppe Rosano—discuss the impact of COVID-19 on patient care and the implications for clinical trial data moving forward.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency is an extremely common comorbidity for 50% to 70% of our patients with heart failure in both the acute and chronic settings. It’s associated with poor exercise capacity, poor quality of life, and increased morbidity and mortality. In hospitalized patients with acute heart failure, iron deficiency is often present independent of anemia.
With that in mind, join Drs. Robert Mentz and Peter van der Meer as they discuss the impact of iron deficiency on patients with heart failure. Find out why it’s time to shift our perception of iron deficiency from a marker of disease outcome to a treatment target.
Host: George L. Bakris, MD
Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU
Guest: Bertram Pitt, MD
Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their progression to ESRD and improve their cardiovascular outcomes. Drs. Rajiv Agarwal, George Bakris, and Bertram Pitt review data from the FIGARO-DKD trial and the FIDELITY Analysis to explore the evolving role of mineralocorticoid receptor antagonists (MRAs) as part of the overall treatment plan for patients with diabetes and CKD. Don’t miss this potentially practice-changing session!
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Michelle Y. Owens, MD
OB-GYN clinicians can improve how they communicate with their patients about hemolytic disease of the fetus and newborn or HDFN. Strategies include encouraging patients to talk about their feelings when learning about this condition and communicating with them in terms that are not overly complex. In this program, Drs. Lee Shulman and Michelle Owens discuss how to break things down for the patient in front of you and explain how to use a read-back approach. This tactic ensures that your patient has absorbed what was discussed and also allows you to identify gaps in her understanding that can be addressed with further counseling.
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
It is well understood that RAASi therapy is critical in the management of patients with heart failure. However, hyperkalemia is common in these patients, and its presence often leads to suboptimal RAASi dosing, which in turn results in poorer patient outcomes. Join Drs. Javed Butler and Giuseppe Rosano as they look at a case presentation and discuss the hows and whys of optimal RAASi dosing in patients with heart failure and recurrent hyperkalemia.
Host: George L. Bakris, MD
Guest: Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
Guest: Robert Toto, MD
When treating patients with heart failure and chronic kidney disease, RAASi therapy should be continued if at all possible. One thing to keep in mind is that an elevation in serum creatinine does not always represent acute kidney injury. In this activity, Drs. George Bakris, Biykem Bozkurt, and Robert Toto examine a case study and discuss transient changes in serum creatinine with hyperkalemia. Join us to find out how and why you should avoid RAAS blockade interruption in these patients.
Host: John E. Anderson, MD
Guest: Simon Heller, MD
Dr. Simon Heller, a Professor of Clinical Diabetes at the University of Sheffield, and honorary consultant physician with the NHS Foundation Trust in the United Kingdom, reflects on the steps we can take to prevent severe hypoglycemia and reduce cardiovascular risk in diabetic patients.
Guest: Daniel Claassen, MD, MS
Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 The cardinal symptoms of nOH include dizziness and lightheadedness,3 but frequently could include syncope, cognitive slowing, generalized weakness, coat-hanger (neck and shoulder) headache, fatigue, orthostatic dyspnea, blurred vision, and orthostatic angina.3 According to the Harris Poll conducted among nOH patients and their caregivers, the symptoms of nOH have a negative impact on activities of daily living. The symptoms are often minimized, poorly recognized/evaluated, or inadequately discussed and addressed.4
Patients with nOH may experience symptoms that can make daily tasks a challenge.1,5 The frequency and severity of symptomatic episodes can be unpredictable,6 and it is this unpredictability of events that contributes to a vicious cycle of nOH.1 In this cycle, fear of symptomatic events and falls may lead patients to reduce physical activity.1,5
References:
- Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.
- Freeman R. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615-624.
- Claassen DO, Adler …
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
John Anderson joins fellow Diabetes Discourse hosts John Buse and Carol Wysham to explore exciting clinical trial results presented at this year's Scientific Session of the American Diabetes Association.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Yvonne Michael, ScD, SM
Dr. Yvonne Michael, an Associate Professor at the Dornsife School of Public Health at Drexel University, discusses risk factors that we should take into consideration when examining postmenopausal patients with coronary heart disease.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Dustin Sulak, DO
Dr. Dustin Sulak, an integrative medicine physician specializing in osteopathy, mind-body medicine, and medical cannabis, talks about the impact of cannabis on the cardiovascular system.
Host: Joseph Saseen, PharmD, BCPS, BCACP, CLS
Guest: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Drs. Cheeley and Saseen will discuss the biological effects of OM-3s and their mechanisms of action and review all recent major clinical trials. Faculty will share practical information for pharmacists on the use of icosapent ethyl vs. generic OM-3s and dietary supplements for ASCVD management.
Upon completion of this activity you will be directed to the activity’s sponsor, Postgraduate Healthcare Education, LLC (PHE) to claim your ACPE credits. Once there you will click, ‘Take Exam’ to claim your credits.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise, Jr., MD
Guest: Christopher Robinson, MD
Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical.
Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.
Guest: John J. Ryan MD, MB, BCh, BAO, MRCPI, FACC, FAHA
John Ryan, MD discusses screening protocols, diagnostic and treatment algorithms, clinical trial evidence, and the vital role of multidisciplinary teams for the management of patients with CTD-PAH in this four-chapter series.
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: Leslie Cho, MD
More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!
Host: George L. Bakris, MD
Guest: Biff F. Palmer, MD
In this case-based activity, Drs. George Bakris and Biff Palmer discuss the benefits of RAAS inhibitors in the patient diagnosed with diabetes, hypertension, and chronic kidney disease. They review the importance of titrating RAAS inhibitors to the highest tolerated recommended dose and identify obstacles to optimizing the dosing of these therapies in patients with comorbidities. They also discuss the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy.
Host: Hector O. Chapa, MD, FACOG
Guest: Marc S. Sabatine, MD, MPH
Cholesterol guidelines recommend nonstatin, LDL-C-lowering therapies in very high risk ASCVD patients if LDL-C goals are not achieved (ESC/EAS dyslipidemia guideline) or if LDL-C is above a specific threshold of 70 mg/dL (AHA/ACC cholesterol guideline). Unfortunately, a substantial number of patients with ASCVD do not achieve LDL-C targets, and nonstatin, LDL-C-lowering therapies are underutilized. Therefore, patients such as those who have experienced an acute coronary syndrome (ACS) remain at increased risk for another major cardiovascular event. Patients with a recent ACS are especially vulnerable to a recurrent cardiovascular event. Nonstatin, LDL-C-lowering therapy with PCSK9 inhibitors and ezetimibe has demonstrated reductions in cardiovascular risk after an ACS. PCSK9 inhibitors have demonstrated robust LDL-C lowering to very low LDL-C levels, with no increase in adverse safety events and with additional cardiovascular risk reduction. Analyses of cardiovascular outcome trial data with PCSK9 inhibition have indicated particularly potent cardiovascular risk reduction in patients with a recent ACS; utilizing PCSK9 inhibitors in these patients enables clinicians to greatly improve their patients’ clinical outcomes. Significant LDL-C reductions, rapid LDL-C goal attainment, and safety have been observed in very early (in-hospital) use of PCSK9 inhibitors. In this educational initiative, lipid expert Dr. Marc Sabatine will discuss guideline …
Host: Paul W. Armstrong, MD
Guest: Justin Ezekowitz, MD, MBBCh, MSc
Is it possible to reduce the nearly 60% one-month rehospitalization rates in patients with worsening heart failure? Dr. Paul Armstrong and Dr. Justin Ezekowitz discuss new therapeutic combinations including soluble guanylate cyclase (sGC) stimulators, as well as the practical applications of new evidence that was presented at the 2021 annual ACC meeting that may change how physicians approach treating their patients with worsening heart failure. Don’t miss out on new information about how sGC stimulators may benefit your patients.
Guest: Brett Nowlan, MD
Metabolic dysfunction is the central driver for conditions with some of the highest mortality rates. Identifying this dysfunction early on is essential to preventing disease progression. Dr. Brett Nowlan, a cardiologist at Cottage Grove Cardiology in West Hartford, Connecticut, explains why.
Guest: Nanette K. Wenger, MD, MACC, MACP, FAHA
What do we need to know about cardiovascular complications during pregnancy? Dr. Nanette Wenger, a Professor of Medicine in the division of cardiology at the Emory University School of Medicine, reviews what cardiologists know about pregnancy complications and the risk of coronary artery disease.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
There is clinical trial-supported evidence for the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure and reduced ejection fraction. RAASi therapy improves both morbidity and mortality outcomes, and its use is now recommended in published guidelines. However, the achievement of target dosing is often limited or interrupted due to the development of hyperkalemia.
In this case-based activity, Drs. Javed Butler and Ileana Piña discuss the importance of optimizing RAASi therapy in patients with heart failure and how the use of potassium binders can help accomplish this goal. They will also review the risks and benefits of potassium binders, in addition to both short- and long-term use of these agents in the treatment of patients with heart failure.
Guest: Christie M. Ballantyne, MD
Host: John J. Russell, MD
According to the Consensus Statement published by the European Atherosclerosis Society, more than 90% (and maybe as high as 99%) of individuals with FH in the US have not been properly diagnosed due to gaps in screening, recognition and classification of FH. If not identified and aggressively treated from an early age, individuals with FH have a 20-fold increased life time risk of heart disease compared to the general population. However, with optimal treatment, an affected individual’s lifetime risk of cardiovascular disease approaches the risk found in the general population. Although the clinical symptoms are not as pronounced in cases of heterozygous FH, both homozygous (HoFH) and heterozygous FH (HeFH) patients still have an elevated risk of developing coronary heart disease at some point in their life. Early diagnosis and treatment for both HoFH and HeFH can significantly reduce the risk of coronary heart disease or delay its onset. Both homozygous and heterozygous FH are serious conditions that require special attention and treatment.
Guest: Nanette K. Wenger, MD, MACC, MACP, FAHA
Is there a relationship between pregnancy complications and subsequent coronary disease? Dr. Nanette Wenger, a Professor of Medicine in the division of cardiology at the Emory University School of Medicine, discusses a recent study exploring this correlation in Black women and shares what cardiologists need to know about pregnancy complications.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
How much do we understand the non-traditional risk factors of atherosclerotic cardiovascular disease, or ASCVD, in women? Dr. Erin Michos, an Associate Professor of Medicine and Director of the Women's Cardiovascular Health Center at Johns Hopkins School of Medicine, meets with Dr. Alan Brown to review ASCVD risk factors in women.
Guest: Andy Arwari, MD
With more patients opting for home-based care over long-term, acute, and office-based care, it’s important that we align with our patients on what’s most important to them and how they want to be cared for, especially those who are nearing the end of life.
That’s why VITAS Medical Director, Dr. Andy Arwari, is here to share the purpose of goals-of-care conversations and how an app can aid in determining if an advanced illness patient is eligible for hospice.
Host: Michael Miller, MD, FACC, FAHA, FNLA
Guest: Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
In 2019, the REDUCE-IT trial studying eicosapentaenoic acid (EPA), a purified form of omega-3 fatty acid, was published and demonstrated a dramatic 25% reduction in major cardiovascular events. In 2020, the STRENGTH trial that used a carboxylic acid formulation of combined EPA and docosahexaenoic acid (DHA), was surprisingly neutral and the study was halted for futility. A recent post hoc analysis of the STRENGTH study failed to show a difference in the primary endpoint in the highest tertile group receiving the EPA/DHA carboxylic acid treatment. Why did these two major omega-3 clinical trials studying patients with elevated triglyceride levels have disparate results? What does this mean for our patients? Join two experts, Drs. Michael Miller and Brian Olshansky, as they assess the different trials and offer their perspective on the clinical and scientific implications of the results.
Host: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: James A. Underberg, MD
Guest: Nathan D. Wong, PhD, MPH
This activity is presented by outstanding educators in the field of lipidology and preventive cardiology. Join Drs. Erin D. Michos, James A. Underberg, and Nathan D. Wong for a deep dive into these hot topics: new pathways to manage high risk in ASCVD, differential biological effects of omega-3 fatty acids, and practical considerations to manage ASCVD risk.
Host: Jennifer Caudle, DO
Guest: Aryeh Shander, MD, FCCM, FCCP
Bleeding is the most common complication of anticoagulant use. And to better care for patients either experiencing acute bleeding or urgently needing surgery, it's critical that clinicians thoroughly understand how to assess, treat, and reverse anticoagulation. Dr. Jennifer Caudle sits down with Dr. Aryeh Shander to discuss some of the different considerations we should take into account when selecting a warfarin reversal option.
Please read full Prescribing Information for Kcentra®.
KCT-0033-APR21
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
How do you mend a broken heart? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, joins Dr. Jerome Lisk to discuss broken heart syndrome and some of its challenges.
Host: Javed Butler, MD, MBA, MPH
Guest: Paul W. Armstrong, MD
Finding the optimal treatment strategy for patients with worsening heart failure with reduced ejection fraction (HFrEF) can be challenging, and long-term outcomes are poor. Can newer therapies and novel mechanisms of action finally help close the treatment gap for these patients? Join Drs. Javed Butler and Paul Armstrong as they explore these new mechanisms of action and provide practical insights into incorporating newly approved therapies into an overall HFrEF treatment plan.
Host: John Buse, MD, PhD
Guest: Anne Louise Peters, MD
SGLT-2 inhibitors have been authorized for diabetic patients in Europe, but is it close to receiving FDA approval in the U.S.? Dr. Anne Peters of USC speaks with Dr. John Buse about SGLT-2 inhibitors and considerations for diabetic ketoacidosis, heart failure, and chronic kidney disease.
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
With no standard criteria available, how do we detect broken heart syndrome in our patients? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, shares what we should be looking for.
Host: Hector O. Chapa, MD, FACOG
Guest: Andrew Little, DO
When vascular access is compromised, intraosseous access, or IO access, can help prevent fatal consequences. What do we need to know about implementing and managing this type of device? Dr. Hector Chapa is joined by Dr. Andy Little, the Associate Program Director for AdventHealth Orlando Emergency Medicine Residency, to share some insight on IO vascular access.
Host: Matthew J. Sorrentino, MD, FACC, FASH
There’s no denying that healthcare professionals across all specialties went above and beyond the call of duty during the COVID-19 pandemic. And cardiologists were no exception. That’s why Dr. Matthew Sorrentino is calling attention to those cardiologists who were nominated by their peers for ReachMD’s Heroes in Healthcare initiative.
Host: Azeem Latib, MD
Guest: Sarah Kohnstamm, MD, FACC
New guidelines on valvular heart disease from the American Heart Association and the American College of Cardiology have recently been published. In this activity, Dr. Latib and Dr. Kohnstamm discuss the etiology of aortic stenosis, as well as apply the new ACC/AHA guidelines to clinical practice.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Salim S. Virani, MD, PhD, FACC, FAHA, FASPC
What is the leading cause of death worldwide? Dr. Matthew Sorrentino sits down with Dr. Salim Virani, who's a professor of medicine at Baylor College of Medicine in Houston, Texas, and the Cardiovascular Disease Fellowship director at Baylor, to discuss how the COVID-19 pandemic has impacted cardiovascular disease globally.
Guest: Satish R. Raj, MD, MSCI
Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 In these patients, there is insufficient compensatory peripheral release of norepinephrine, the major neurotransmitter responsible for blood pressure maintenance, upon standing or following postural change.2-4 Due to this norepinephrine deficiency, there is inadequate vasoconstriction to maintain blood pressure or cerebral blood flow.1,5 This may lead to symptoms of nOH which may increase the risk of falls and lead to serious consequences.2,3,6
Here. Dr. Satish Raj, Professor of Cardiac Sciences at the Libin Cardiovascular Institute at the University of Calgary's Cumming School of Medicine and Medical Director of Calgary Autonomic Clinic, discusses the pathogenesis of nOH, as well as the mechanisms behind therapeutic approaches to controlling its effects.
References:
- Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011:21(2) 69-72.
- Low PA. Neurogenic orthostatic hypotension: pathophysiology and diagnosis. Am J Manag Care. 2015;21(suppl 13):s248-s257.
- Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009:119(1):139-146.
- Freeman …
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Keith C. Ferdinand, MD
Dr. Keith Ferdinand, Tulane University's Gerald S. Berenson Endowed Chair in Preventive Cardiology and Professor of Medicine at the Tulane University School of Medicine, joins Dr. Alan Brown to discuss cardiovascular healthcare disparities among African Americans and what we can do to improve access to care.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: C. Michael Gibson, MD, FSCAI
Following a major cardiovascular event, what interventional strategies should we be considering? Dr. Matthew Sorrentino joins Dr. Michael Gibson, a professor of medicine and cardiology at the Beth Israel Deaconess Medical Center at Harvard Medical School in Boston, Massachusetts to discuss antiplatelet and anticoagulation strategies for patients with cardiovascular disease.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Ronnie Fass, MD
Non-cardiac chest pain, NCCP, is chest pain in patients who do not have heart disease. How do we identify and diagnose NCCP? Stay tuned as Dr. Peter Buch talks with Dr. Ronnie Fass, Chief of the Division of Gastroenterology and Hepatology, on the important aspects of non-cardiac chest pain.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Suneet Mittal, MD FACC FHRS
The development of cardiac devices enhanced by wireless remote monitoring has changed the way cardiologists care for their patients. With that in mind, Dr. Matthew Sorrentino discusses remote monitoring in cardiology with Dr. Suneet Mittal, medical director of the Snyder Center for Comprehensive Atrial Fibrillation at the Valley Hospital in Ridgewood, New Jersey.
Guest: Hemal Gada, MD
Guest: Vijay Iyer, MD, PhD, FACC
TAVR-related stroke is a real risk that can seriously impact your patients' quality of life. In this video, Drs. Hemal Gada and Vijay Iyer sit down to discuss the effects of stroke, the role of cerebral embolic protection, and the importance of protecting patients' brains.
Physicians in this episode were compensated for their participation.
Media provided courtesy of Boston Scientific or its affiliates.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Arun Sharma, PhD
Can low gravity and space flight impact our cardiac function? Dr. Arun Sharma, a stem cell biologist at Cedars-Sinai Medical Center in California, joins Dr. Alan Brown to discuss the impact of outer space on the heart.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Alan S. Brown, MD, FACC, FAHA, FNLA
The development of statin medications has pushed preventative treatment to the forefront of cardiology. How have advancements in prevention impacted the field? Heart Matters hosts Dr. Matthew Sorrentino and Dr. Alan Brown sit down to discuss prevention in cardiovascular disease and how cardiologist treat their patients.
Guest: Joshua Stolker, MD
The 2020 American College of Cardiology Expert Consensus Decision Pathway provides a change in mindset for the cardiology field when it comes to treating patients with type 2 diabetes with established cardiovascular disease. Here to walk us through these updated recommendations is Dr. Joshua Stolker, an interventional cardiologist at Mercy Clinic Heart and Vascular in Saint Louis, Missouri.
To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US20DI00430 January 2021
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Dr. Matthew Sorrentino sits down with Dr. Erin Michos, an Associate Professor of Medicine and the Director of Women’s Cardiovascular Health and the Associate Director of Preventive Cardiology at Johns Hopkins Medicine to discuss the ACC/AHA cholesterol guidelines, originally released in 2013 and updated in 2018.
Host: Jennifer Caudle, DO
Guest: Steve R. Ommen, MD
Dr. Steven Ommen, a cardiologist and medical director of the Hypertrophic Cardiomyopathy Clinic at Mayo Clinic and the chair of the 2020 AHA/ACC Hypertrophic Cardiomyopathy Guideline Writing Committee, sits down with Dr. Jennifer Caudle to discuss the committee’s updated guidelines.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org.
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Nanette K. Wenger, MD, MACC, MACP, FAHA
Previously thought to mostly affect men, heart disease puts an equal or greater number of women at risk. What do we need to know about protecting them from this life-threatening condition? Dr. Nanette Wenger, a Professor of Medicine in the division of cardiology at Emory University School of Medicine, joins us to discuss the prevalence of heart disease among women.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: Sripal Bangalore, MD, MHA
For patients who have recently experienced a myocardial infarction, LDL cholesterol management is critical to help reduce the risk of recurrent CV events. At a time of the COVID-19 pandemic, when patient behavior and clinical practice methods are impacted, what can we do to improve CV outcomes for these patients? Join Drs. Pam Taub and Sripal Bangalore as they explore why patients with a recent myocardial infarction occurring within the previous 12 months are among the highest risk for recurrent CV events and what can be done to better manage that risk.
©2020 Amgen Inc. All rights reserved. USA-145-82480 12/20
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host: Matthew Sorrentino, MD
Developments in the healthcare community have changed the field of preventative cardiology. But how have they impacted cardiology care? Heart Matters hosts Dr. Alan Brown and Dr. Mathew Sorrentino examine adherence to medicine, improvements to compliance, and new entries into the marketplace surrounding cardiology.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Daniel T. Lackland DrPH
For decades, news reports have focused on the prevalence of high blood pressure among adults in the U.S. But a recent study claims that blood pressure among these adults has actually decreased between 1960 and 2005. Here to divulge the surprising results of his study and discuss systolic blood pressure improvements in adults in the U.S. is Dr. Daniel Lackland.
Host: Ewa A. Jankowska, MD, PhD, FESC
Hospitalizations due to acute heart failure represent a growing healthcare problem and a large economic burden. Iron deficiency, irrespective of anemia, is prevalent among this population and is associated with a high risk for increased mortality and rehospitalization. Tune in to discover the latest data from the AFFIRM-AHF trial. What does this new information reveal about treatment with intravenous iron in patients with acute heart failure?
Host: Stefan D. Anker, MD, PhD
Guest: Javed Butler, MD, MBA, MPH
Guest: Ewa A. Jankowska, MD, PhD, FESC
Guest: Josep Comin-Colet, MD, PhD
How does treatment of iron deficiency affect outcomes in patients hospitalized for acute decompensated heart failure? This late-breaking video brief reviews the topline results of the AFFIRM-AHF data released at the 2020 American Heart Association Scientific Sessions and provides reactions from several heart failure experts on what these data mean on a global level.
Host: Matt Birnholz, MD
Guest: Juan A. Crestanello, MD
Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.
Cardiac reoperations are complex procedures that require a highly advanced set of surgical techniques. With more patients than ever before going back for reoperations, how can we help surgery outcomes? Tune in as Dr. Matt Birnholz and Dr. Juan Crestanello discuss those challenges and more.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org.
Host: Jennifer Caudle, DO
Guest: Lisa A. Coco, CRNP
Guest: Deborah Hinnen, APN, BC-ADM, CDCES, FAAN
Guest: Davida F. Kruger, CNP
When a patient with diabetes has cardiovascular disease, they’re at greater risk for morbidity and mortality. That’s why the American Diabetes Association’s 2020 Standards of Medical Care in Diabetes aim to address this and other health risks, and here to walk us through this new treatment algorithm are nurse practitioners Lisa Coco, Debbie Hinnen, and Davida Kruger.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00343 October 2020
Host: Mikhail Kosiborod, MD
Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Jennifer N. Avari Silva, MD
While we know that the lungs are deeply affected by COVID-19, they’re far from the only organ to be ravaged by this disease. Dr. Richard Vander Heide, Professor and Director of Pathology Research at LSU Health, New Orleans School of Medicine, joins Dr. Alan Brown to discuss how he led a team of pathologists that performed autopsies on COVID-19 patients to discover the resulting cardiac changes.
Host: Jennifer Caudle, DO
Guest: Anjali Owens, MD
Without any targeted therapies available for inherited cardiomyopathy, how can we treat our patients coping with its debilitating symptoms? Here to share her diagnostic and management strategies along with key data from a recent study is Dr. Anjali Owens, Medical Director at the Center for Inherited Heart Disease at Penn Medicine.
Host: Jennifer Caudle, DO
Guest: Kathryn J. Ruddy, MD
Guest: Joerg Herrmann, MD
As the number of cancer survivors continues to grow due to treatment advances, so too do the long-term impacts like cardiovascular complications. That’s why the field of cardio-oncology has emerged, and to learn more, Dr. Jennifer Caudle speaks with Drs. Kathryn Ruddy and Joerg Herrmann from the cardio-oncology clinic at the Mayo Clinic to talk about the field that’s devoted to improving cardiovascular health both during and after cancer therapy.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: Linda Bernstein, Pharm.D.
In this episode of The Drug Report, pharmacist Dr. Linda Bernstein highlights some diabetes medications that have achieved or are pending approval for new indications pertaining to cardiovascular disease risk reduction.
Host: Matt Birnholz, MD
Guest: Howard C. Herrmann, MD
Twelve years after performing the first transcatheter aortic valve replacement, Penn Medicine continues to gain momentum in the transformation of cardiovascular transcatheter therapies. Dr. Howard Herrmann recounts the evolution in alternative technologies to improve patient safety and outcomes and the role these advancements have in shaping how we approach treatment.
Host: Jennifer Caudle, DO
Guest: Ashira Blazer, MD
Did you know that African Americans are three times as likely to be diagnosed with lupus than other demographic groups? To make matters worse, being diagnosed with lupus doubles their risk of kidney disease, stroke, and heart attacks.
To address this growing health threat among African Americans, Dr. Jennifer Caudle is joined by Dr. Ashira Blazer, Instructor in the Department of Medicine and Rheumatologist at NYU Langone Health, to discuss diagnosis, comorbidities, and various treatment options for your lupus patients.
Correction Note: Dr. Blazer has updated that in the U.S., variation homozygosity for APOL1 is present in 13% of the African American population.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough is joined by Dr. Mark Zucker, Director of the Cardiothoracic Transplantation Program at RWJBH/Newark Beth Israel Medical Center, and his HCM patient and founder of the Hypertrophic Cardiomyopathy Association, Lisa Salberg, to discuss her inspiring story and the importance of early diagnosis.
Host: Maurice Pickard, MD
Guest: Bob Mitchell
Quite suddenly, Bob Mitchell became very sick. He would endure three near-fatal episodes of ventricular tachycardia due to a heart muscle comprised of 54% scar tissue, as well as heart surgeries, two harrowing months of waiting on the transplant list for a new heart on life-supporting IV drips (during which time a malignant tumor was detected in his kidney), partial nephrectomy surgery to remove the cancer, another month of waiting, a 12-hour heart and kidney transplant surgery, and 100 days on life support in four different hospitals.
Host Dr. Maurice Pickard talks with novelist Bob Mitchell, author of Time for a Heart-to-Heart: Reflections on Life in the Face of Death about his inspiring story of the triumph of hope in the face of the direst of circumstances.
Host: Brian P. McDonough, MD, FAAFP
Guest: Benjamin Levine, MD, FACC
Poor fitness in middle age is a strong predictor of a person’s future risk of heart failure. Prolonged exercise training, including a regular routine of high-intensity and moderate-intensity workouts, can forestall the effects of sedentary aging by preventing increased left ventricular stiffness.
Dr. Benjamin Levine joins host Dr. Brian McDonough to talk about how regular exercise training may provide protection against the sedentary aging of the heart by preventing an increase in cardiac stiffness.
Dr. Levine is a Professor of Internal Medicine at the UT Southwestern Medical Center and the Director of Autonomic Function and Cardiopulmonary Clinics at the Institute for Exercise and Environmental Medicine at Texas Health Presbyterian Hospital.
Host: John J. Russell, MD
Guest: Thomas Doyle, MD
About 40,000 babies are born with Congenital Heart Disease each year, making it one of the most common birth defects and causes of infant death in the US. CHD is usually present at birth but shows very few outward signs and, in most cases has no known cause or origin.
New and evolving surgical techniques, along with the dawn of pediatric heart transplant, are transforming the field of pediatric cardiology and offer new options for CHD patients.
Host Dr. John Russell talks with Dr. Thomas Doyle about how continued research, improved surgical treatments and, emerging technology have altered the course of treatment for CHD, resulting in approximately 69% of children with CHD now living to age 18.
Dr. Thomas Doyle is the Ann and Monroe Carell Jr. Family Associate Professor of Pediatrics at Vanderbilt University. Dr. Doyle was a 2016 Project Heart CHD research grant recipient.
Host: Jennifer Caudle, DO
Guest: Karol Watson, MD, PhD
Under the 2017 Hypertension Guidelines, 46 percent of U.S. adults have high blood pressure which is up from 32 percent under the old benchmark. This interview covers the key information physicians need to know from the new guidelines in order to improve blood pressure control rates.
Host Dr. Jennifer Caudle is joined by Dr. Karol Watson, an attending cardiologist and a Professor of Medicine/Cardiology at the David Geffen School of Medicine at UCLA. Dr. Watson is a principal investigator for several large National Institutes of Health research studies, including the Diabetes Prevention Program Outcomes Study and the Multi-Ethnic Study of Atherosclerosis. She reacts to the new guidelines and reflects on what these changes could mean to patients.
The American Medical Association's M.A.P. framework and blood pressure improvement program is dedicated to helping health care providers improve blood pressure control in their adult patient populations, and a new AMA resource can help you succeed in Medicare’s Merit-Based Incentive Payment System (MIPS) while you manage and treat high blood pressure. This resource outlines the different measures that relate to hypertension management in each MIPS performance category, potential MIPS score results, and related AMA resources that can help you improve the health of …
Host: Shira Johnson, MD
Physicians spend their entire careers striving to heal sick patients. But when these care providers become patients themselves, the abrupt reversal of roles can make for difficult adjustments.
Host Dr. Shira Johnson sits down with Dr. John Mulligan, VP for Emergency Room Physicians Medical Group and a practicing emergency physician, to share his experience, takeaways, and advice for transitioning from doctor to patient.
Host: Matt Birnholz, MD
Guest: Denise Devine
What if there was a way to monitor vital signs in real time? Denise Devine, Co-Founder of RTM Vital Signs, LLC, is working on just that. She is joined by Dr. Matt Birnholz at the Villanova Health Summit to discuss this innovative technology in development, which opens up the possibility of collecting continuous health data from patients to enhance point-of-care treatments.
Host: Barnett Mennen, MD
Guest: Grace Wang, MD, FACS
Unclogging patient arteries is a key step to preventing stroke in patients with arterial disease. Whether it be preventing the operative stage, or surgery itself, advances in treatment at Penn Medicine are seeking to lessen the effects of arterial disease.
Host Dr. Barry Mennen welcomes Dr. Grace Wang, vascular surgeon and Director of the Vascular Laboratory at the Hospital of the University of Pennsylvania. Dr. Wang highlights the importance of early detection in arterial disease, as well as the symptoms and risk factors of the disease. She will also discuss the current and upcoming surgical intervention options at Penn Medicine.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough chats with cardiologist Dr. Andrew Waxler about the life and career lessons he learned from his unique family upbringing as the nephew of celebrity comedian Joan Rivers. He then draws on these lessons to describe important steps people can take to live healthy lifestyles for best cardiac outcomes.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Robert Kloner, Vice President of Translation at Huntington Medical Research Institutes and Professor of Medicine in the Cardiovascular Division of Keck School of Medicine at the University of Southern California.
Dr. Kloner discusses the cardiovascular risk factors associated with erectile dysfunction, safety and efficacy of erectile disfunction drugs, and benefits vs risks of supplementing with testosterone.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Rhoda Cooper-DeHoff. Dr. Cooper-DeHoff is an Associate Professor in the Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine of the Colleges of Pharmacy and Medicine at the University of Florida. She is also Associate Director of the Center for Pharmacogenomics at this institution.
Dr. Cooper-DeHoff discusses the rise of pharmacometabolomics, genomic testing, and pharmacogenetic testing in lipidology, with particular emphasis on predictive mapping for statin responses.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dave Dixon, PharmD, Clinical Pharmacist and Associate Professor of Pharmacology at Virginia Commonwealth University School of Pharmacy. Dr. Dixon is also a Board Certified Pharmacotherapy Specialist, Clinical Lipid Specialist, and Fellow of the National Lipid Association. He serves as a Regional Representative for the Southeast Chapter of NLA and on the Journal of Clinical Lipidology Editorial Board.
Dr. Dixon discusses guidelines for treating hypertriglyceridemia, effective therapies for reducing triglyceride levels, and emerging lipid-lowering therapies in development.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Eugenia Gianos. Dr. Gianos is an assistant professor in the Department of Medicine and co-clinical director of the Center for the Prevention of Cardiovascular Disease at the NYU School of Medicine.
Dr. Gianos discusses the effectiveness, potential side effects, and patient outcomes with PCSK9 antibodies for management of dyslipidemia.
[Read the Article]
The FDA recently approved a new class of cholesterol-lowering drugs called PCSK9 inhibitors. These new medications could substantially reduce heart attacks, strokes and cardiovascular deaths, however they are very expensive. A new study evaluated the cost-effectiveness of this therapy and how increased use might affect the U.S. healthcare system.
Researchers from the University of California San Francisco used a simulation model that included all U.S. adults 35 and older and evaluated outcomes such as expected numbers of deaths due to cardiovascular disease, heart attacks and strokes, and balanced this with the cost and potential benefits of these drugs.
With an estimated 9 million people eligible for this therapy and a price of $14,000 per patient per year, researchers estimated that total prescription drugs expenditures could increase by 40 percent. In order to be cost-effective, the PCSK9 inhibitor costs would have to come down to about $4,000 a year.
[Watch more videos of The JAMA Report]
[Read the Article]
Patients who might benefit from a heart valve replacement but are too ill for open heart surgery can sometimes undergo a less invasive procedure known as transcatheter aortic valve implantation or "TAVI". About 10% of patients undergoing TAVI can experience small strokes and related brain injury as a complication. A new study found that the use of a cerebral protection device, which captures debris dislodged from blood vessels during the TAVI procedure, reduced the number and volume of brain lesions seen on MRI.
Researchers from the University of Leipzig Heart Center, Germany studied 100 patients with an average age of 80 who underwent TAVI. Half of the patients received the cerebral protection device and the other half did not. Patients underwent brain MRIs before the implantation and again at 2 and at 7 days after the procedure. The results found that using the filter device helped to decrease the number of brain lesions seen in the brain by about half.
[Watch more videos of The JAMA Report]
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG
Midlevel providers help fill the gap in health care coverage across the country. Nurse practitioners, in particular, have the distinct capabilities to work independently in a variety of areas including consultations, treatments, and authorization of durable medical equipment.
Host Dr. Renee Allen chats with Patrick Washington, a board-certified nurse practitioner in family medicine, about the role NPs play in the healthcare system, how education requirements are evolving, and where NP duties differ from those of physician assistants (PAs).
Host: Jennifer Caudle, DO
Guest: K. Akaya Smith, MD
Pulmonary Arterial Hypertension (PAH): Who is at greatest risk for developing it? What do practitioners need to know about diagnosing, treatment and the overall prognosis? Host Dr. Jennifer Caudle welcomes Dr. Akaya Smith, Medical Director for Pulmonary Hypertension Program and Assistant Professor of Medicine at the Hospital of the University Pennsylvania. Dr. Smith answers these questions, as well as, the Penn Center of Excellence for Pulmonary Hypertension.
Host: Jennifer Caudle, DO
Pectus excavatum is an uncommon condition, but a highly impactful one for those who are born with it. What do physicians need to know about pectus excavatum when encountering it in practice, and what new advances in treatment are on the horizon?
Host Dr. Jennifer Caudle sits down with Dr. Dawn Jaroszewski, a cardiovascular surgeon at the Mayo Clinic, to talk about research updates and treatment options for patients with pectus excavatum.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Patients in lipidolgy clinics sometimes undergo diagnostic workups for mild liver enzyme elevations, and in select cases a diagnosis of non-alcoholic fatty liver disease will be made. How does this diagnosis compare with the more inflammatory alcoholic fatty liver disease, and what roles should the lipidologist play in response to these findings?
Dr. David Cohen, Professor of Medicine at Harvard Medical School and Director of Hepatology at Brigham and Women's Hospital, joins host Dr. Alan Brown to discuss the pathogenesis and management of non-alcoholic fatty liver disease.
Host: Jennifer Caudle, DO
Guest: Francis Marchlinski, MD
Host Dr. Jennifer Caudle welcomes Dr. Francis E. Marchlinski, Richard T. and Angela Clark President's Distinguished Professor and Director of the Electrophysiology Laboratory at the University of Pennsylvania. Dr. Marchlinski will review the epidemiology of PVCs, the kinds of problems that PVCs can cause, and how these problems manifest as symptoms in patients. He will also review the effectiveness of catheter ablation as a current treatment option for ventricular tachycardia (VT), a potenially serious complication of PVC's.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Joining Dr. Alan Brown to discuss the pharmacokinetic data behind drug interactions between treatments for complex lipid abnormalities is Dr. Barbara Wiggins, Pharm.D, clinical pharmacy specialist in cardiology at the Medical University of South Carolina and adjunct professor at the South Carolina School of Pharmacy. Dr. Wiggens has served as a member of the cardiovascular expert panel for the United States Pharmacopoeia.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Robert Wild, MD, MPH, D.Phil.
Recorded live at the recent Annual National Lipid Association meeting, Dr. Alan Brown welcomes Dr. Robert Wild to discuss types of dyslipidemia that clinicans may see in women of child bearing age, particularly those using hormonal contraception. The two discuss ways for clinicians to trace the source of dyslipidemia in these women, from primary to secondary causes, and how this knowledge can guide future contraception choices.
Dr. Robert Wild is Professor of OB/GYN and Adjunct Professor in Biostatistics and Epidemiology at the University of Oklahoma. He is also Adjunct Professor in Epidemiology at the University of Pittsburgh, and Adjunct Professor of Nutrition at Oklahoma State University.
Host: Shira Johnson, MD
Guest: Charles N. Walker, MD
Dr. Shira Johnson speaks with Dr. Charles Walker, Assistant Professor of Surgery in the Department of Urology at Yale University School of Medicine. The two focus on erectile dysfunction as a common complication for patients dealing with diabetes and heart disease, and ways that clinicians can help patients manage this problem through lifestyle modifications. Dr. Walker also introduces emerging pathophysiological understandings of ED as a potential predictor of diabetes.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Joyce Ross
Host Dr. Alan Brown welcomes Joyce Ross, nurse practitioner and President of the National Lipid Association. Joyce is a consultative education specialist in Cardiovascular Risk Intervention with the University of Pennsylvania Health System. She is the first Nurse Practitioner elected as President of the NLA.
Ms. Ross introduces her goals for the upcoming year, including novel efforts on behalf of the NLA to help combat America's obesity epidemic.
Host: Matt Birnholz, MD
Guest: Patricia Sulak, MD
The American Heart Association instituted a Strategic Impact Goal to reduce the incidence of cardiovascular deaths and disabilities by 20% by 2020.
Host Dr. Matt Birnholz chats with Dr. Patricia Sulak, Endowed Professor of the Texas A&M University College of Medicine about the 7 key health metrics to reduce cardiovascular deaths including blood pressure, physical activity, and healthy diet, among others.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown welcomes Dr. Seth Martin, cardiologist and assistant professor of medicine at the Johns Hopkins University School of Medicine with a joint appointment in epidemiology at the Johns Hopkins Bloomberg School of Public Health. Dr. Martin is a faculty member in the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.
Dr. Martin discusses the pursuit of lipid profiles on a national level, utilizing Big Data from health records and clinical trials to develop better understandings of cardiovascular risk and theraputic efficacies.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA
Host Dr. Alan Brown welcomes Joyce Ross, MSN, CRNP, FNLA, President-Elect of the National Lipid Association. Joyce serves as a consultative education specialist in cardiovascular risk intervention with the University of Pennsylvania Health System. Their discussion focuses on lipid management to reduce atherosclerotic cardiovascular disease (ASCVD) risk in elderly patient populations. Thhis interview was recorded live at the National Lipid Association in San Diego, California for the 2016 Spring Clinical Lipid Update.
[Read the Article]
An estimated 15 million Americans do some kind of rotating shift work, including overnights, evenings and early morning shifts. But can this type of shift work increase the risk of coronary heart disease? A new study examined the link between rotating night shift work and heart disease in a group of female nurses.
Researchers at Brigham and Women's Hospital used data from the Nurses' Health Studies (1 and 2), which followed participants for a twenty-four year period. They specifically looked at 189,000 women who reported their lifetime exposure to rotating night shift work. Over the course of the study period, more than 10,000 new cases of coronary heart disease were reported.
The results suggested that rotating night shift work was associated with modest risk of coronary heart disease, but further research is needed to help determine whether the association is related to specific work hours and/or individual characteristics.
[Watch more videos of The JAMA Report]
Host: Jennifer Caudle, DO
Guest: Yuli Kim, MD
Advancements in cardiac surgery and medical care for pediatric patients over the past decades have produced a sizeable population of adults living with congenital heart disease. These adults and their unique health care needs expose an emerging gap in expertise for the cardiology community, where training in congenital heart disease management has traditionally been the provence of pediatric subspecialists. How can these adult patients find cardiologists familiar with their particular anatomy and problems, and what special care strategies must cardiologists be familiar with to provide optimal care?
Dr. Jennifer Caudle will discuss the selective health care needs and personalized management strategies for adults with congenital heart disease with Dr. Yuli Kim, Medical Director of the Philadelphia Adult Congenital Heart Disease Center and Assistant Professor of Medicine & Pediatrics at the University of Pennsylvania and the Children's Hospital of Philadelphia.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown welcomes Dr. Steven Nissen, Chairman of the Department of Cardiovascular Medicine and Professor of Medicine at the Lerner School of Medicine of the Cleveland Clinic. The two focus on some of the major developments in lipidology today, from roles of intravascular ultrasound to updates in clinical drug trials to perspectives on past and present guideline recommendations.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Harold Bays, MD, FNLA
Dr. Alan Brown welcomes Dr. Harold Bays, President of the Southeast Lipid Association and President of the Louisville Metabolic and Atherosclerotic Research Center in Louisville, KY. Dr. Bays led a novel educational effort to provide an annual summary of clinical lipidology to readers of the Journal of Clinical Lipidology. With insightful commentaries of value to lipidologists and generalists alike, the annual summary is expected to pave new ground in the ongoing effort to keep clinicians up to date with the field.
Host: Jennifer Caudle, DO
Guest: Nimesh Desai, MD
Complex aortic diseases, feared by clinicians and the general public alike, are often labeled "silent killers" due to their unnerving pattern for developing insideously prior to presenting as acute crises. Even more concerning, the symptoms of aortic diseases are typically vague and difficult to diagnose without a high degree of clinical suspicion. For these reasons, the speed of diagnosis and treatment can determine whether patients live or die from aortic disease. Host Dr. Jennifer Caudle welcomes Dr. Nimesh Desai, attending cardiac surgeon and Director of the Thoracic Research Program at the University of Pennsylvania, to discuss innovative medical and surgical approaches to complex aortic diseases. The two categorize these disease states specifically, examine which patient populations are at highest risk, and review methods to help clinicians reach faster life-saving diagnoses.
[Read the Article]
Among obese older patients with an increasingly common type of heart failure, calorie restriction and/or exercise training improved their ability to participate in physical activity without experiencing shortness of breath, according to a new study.
Heart failure with preserved ejection fraction (HFPEF) is the most rapidly increasing form of heart failure in the United States. Although the heart pumps normally, it does not fill with enough blood because the lower chamber of the heart is too stiff. More than eighty percent of patients with HFPEF are overweight or obese. Despite multiple studies, so far, no currently available medications have improved symptoms in patients with HFPEF.
Researchers from the Wake Forest School of Medicine randomly assigned 100 older obese participants with HFPEF to 20 weeks of diet, exercise, or both. They found that the exercise participants lost three percent of body weight, the diet group lost seven percent and the combined group lost ten percent of body weight. Patients in both the diet and exercise groups showed improvement in their ability to participate in exercise without significant symptoms.
[Watch more videos of The JAMA Report]
Host: Patrice L Basanta-Henry, MD, MHSc, FACOG
Host Dr. Patrice Basanta Henry welcomes Dr Nzinga Harrison, Addiction Medicine & Psychiatrist, Campaign Psychiatrist for Let's Get Mentally Fit!, and, the CMO of ANKA Behavioral Health Incorporated. Dr. Harrison will discuss the importance of non-pyschiatric clinicians in recoginizing mentail illness, those specific illnesses where there is a higher chance of comorbidity of psychiatric illness, and best practices & tools avaialble for health care providers.
Host: Jennifer Caudle, DO
Guest: Scott O. Trerotola, MD, FACR, FSIR
Is there a way to predict complex removal of inferior vena cava filters, and if so, what is the success rate? Dr. Scott Trerotola adresses these and other questions in details. Dr. Trerotola is Stanley Baum Professor at the Hospital of the University of Pennsylvania, Chief of Vascular and Interventional Radiology and Vice Chair for Quality of the Department of Radiology at the University Of Pennsylvania Medical Center.
Host: John J. Russell, MD
Thought of as the seat of our soul, then as a mysteriously animated object, the heart is still more a mystery than it is understood. Rob Dunn, evolutionary biologist and author of The Man Who Touched His Own Heart, tells the raucous, gory, mesmerizing story of the heart, from the first "explorers" who dug up cadavers and plumbed their hearts' chambers, through the first heart surgeries-which had to be completed in three minutes before death arrived-to heart transplants and the latest medical efforts to prolong our hearts' lives, almost defying nature in the process.
CDC's Dr. John Iskander and Dr. Janet Wright discuss the progress that has been made with Million Hearts®, along with the work that is still needed to reach the goal of preventing one million heart attacks and strokes by 2017.
Providers should:
- Utilize electronic health records to proactively reach individuals with elevated blood pressure or cholesterol
- Place emphasis on detecting cases of uncontrolled high blood pressure which are hiding in plain sight
Communities can:
- Implement smoke-free policies to lower exposure to smoke
- Adopt food procurement policies that make healthier foods more readily available
- Encourage and train individuals to self-monitor their blood pressure
[Read the Article]
Financial incentives for physicians or patients are one way healthcare organizations are trying to improve health outcomes. A new study examined whether providing these financial incentives would help improve low-density lipoprotein cholesterol (LDL-C) in patients with a high-risk for cardiovascular disease.
Researchers from the University of Pennsylvania, Philadelphia studied 1,500 patients and 340 primary care physicians. Physicians were randomly assigned to one of four groups. One group solely focused on providing physicians with financial incentives, while another group focused on financially rewarding patients when they showed improvements in their cholesterol levels. A third group consisted of shared incentives for both physicians and patients, while the last group (a control group) did not receive any financial incentives.
Overall, shared financial incentives for both physicians and patients, but not incentives to physicians or patients alone, resulted in a significant reduction of LCL-C levels at 12 months.
[Watch more videos of The JAMA Report]
Host: Jennifer Caudle, DO
Guest: Pavan Atluri, MD
What are the latest advances in minimally invasive & robotic operations? And, which patients are candidates for robotic procedures? Host Dr. Jennifer Caudle welcomes Dr. Pavan Atluri, Assistant Professor of Surgery; Director of the Cardiac Transplantation and Mechanical Circulatory Assist Program; and, Director of the Minimally Invasive and Robotic Cardiac Surgery Program in the Division of Cardiovascular Surgery at the University of Pennsylvania. Dr. Atluri will discuss the latest advancements at Penn Medicine where he and his colleagues have been working for several years to perfect the robotic, minimally invasive, mitral valve repair procedure.
And, don't forget to view some of the additional content below.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Allan Sniderman, MD
Risk is calculated by a variety of algorithms, all of which produce an estimate for that individual based on age, gender, cholesterol, blood pressure, and smoking history. The estimate is critical to clinical decision-making, but how accurate is it? Host Dr. Alan Brown welcomes Dr. Allan Sniderman, Edwards Professor of Cardiology at McGill University, to discuss why we should pay more attention to the causes, and less to the risks, of cardiovascular disease.
Supported by an Educational Grant from AstraZeneca.
This week, hosts Mark Masselli and Margaret Flinter speak with Dr. Darshak Sanghavi, Director of the Preventive and Population Healthcare Models Group at the Center for Medicare and Medicaid Innovation which has launched the "Million Hearts" campaign to reduce cardiovascular disease. The 5-year campaign is CMS's largest experiment to date on pay-for-performance practice models and is supporting practices to follow the American College of Cardiology and the American Heart Association Risk Assessment guidelines to help patients avoid a million heart attacks or strokes.
[Read the Article]
Out-of-hospital cardiac arrest is a major public health issue, accounting for approximately 200,000 deaths per year in the United States. A new study examined whether increased use of defibrillators and cardiopulmonary resuscitation (CPR) by first responders and bystanders could help increase survival for people who experience an out-of-hospital heart attack.
In recent years, statewide initiatives in North Carolina have encouraged improvement in the use of CPR and automated external defibrillators (AEDs) by training more members of the general public.
Bystander-initiated CPR was associated with a greater likelihood of survival with favorable neurologic outcome. The combination of bystander CPR and first responder defibrillation increased from 14 percent in 2010 to 23 percent in 2013. Results found, patients who received bystander or first responder interventions before arrival of the emergency medical services (EMS) were more likely to survive compared to those who received EMS intervention alone.
[Watch more videos of The JAMA Report]
JAMA Report videos provided pursuant to license. ©2015 American Medical Association, publisher of JAMA® and The JAMA Network® journals.
Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial Andrew Appelboam, FRCEM, Adam Reuben, FRCEM, Clifford Mann, FRCEM, James Gagg, FRCEM, Prof Paul Ewings, PhD, Andrew Barton, MSc, Trudie Lobban, MRCP, Mark Dayer, FRCP, Jane Vickery, MSc, Prof Jonathan Benger, MD on behalf of the REVERT trial collaborators
The Lancet. 2015; DOI:10.1016/S0140-6736(15)61485-4
Published Online: 24 August 2015
Background: The Valsalva manoeuvre is an internationally recommended treatment for supraventricular tachycardia, but cardioversion is rare in practice (5–20%), necessitating the use of other treatments including adenosine, which patients often find unpleasant. Researchers assessed whether a postural modification to the Valsalva manoeuvre could improve its effectiveness.
Methods: The study authors did a randomised controlled, parallel-group trial at emergency departments in England. They randomly allocated adults presenting with supraventricular tachycardia (excluding atrial fi brillation and flutter) in a 1:1 ratio to undergo a modified Valsalva manoeuvre (done semi-recumbent with supine repositioning and passive leg raise immediately after the Valsalva strain), or a standard semi-recumbent Valsalva manoeuvre. A 40 mm Hg pressure, 15 s standardised strain was used in both groups. Randomisation, stratified by centre, was done centrally and independently, with allocation with serially numbered, …
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Medication Adherence: is it the Achilles Heel in your therapies for patients with dyslipidemia? Dr. Lynne Braun, nurse practitioner in the Preventive Cardiology Center and the Heart Center for Women, and Professor in the Department of Adult Health Nursing at the Rush College of Nursing in Chicago, targets three critical barriers to lipid medication adherance: weak patient-provider relationships, health illiteracy, and poor health care transitions after hospital discharge.
Supported by an Educational Grant from AstraZeneca.
Host: John J. Russell, MD
In the 1940's, popular American President Franklin D. Roosevelt developed a serious illness that went undetected by the media and general public. That illness was severe hypertensive heart disease, and unbeknownst to everyone outside the White House, the medical staff may have been hiding its progression to protect the President's image during his last campaign. Did the secrecy cost him his life prematurely, or were treatments too limited at the time to make a fundamental impact? Furthermore, had it been known by everyone, would the President have been reelected?
Joining Dr. John Russell to discuss the fascinating history of a possible White House medical conspiracy of old is Dr. W. Bruce Fye, author of Caring for the Heart: Mayo Clinic and the Rise of Specialization,
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Dr. Alan Brown welcomes Dr. Peter Jones, Associate Professor of Medicine and Atherosclorosis/Lipidology at Baylor College of Medicine in Houston, TX. They review special populations in the treatment of dyslipidemia, including Asians, women, elderly patients, and the immune-compromised.
Supported by an Educational Grant from AstraZeneca.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Keith C. Ferdinand, MD
Host Dr. Alan Brown is joined by Dr. Keith C. Ferdinand, Professor at Tulane University School of Medicine in New Orleans, Louisiana. Dr. Ferdinand reviews the etiologies, diagnostic challenges, and management considerations for selective cardiac health issues prevalent in African American populations, from hypertension to coronary arterial calcium plaques to lipid levels.
Supported by an Educational Grant from AstraZeneca.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA
One of the most recurrent questions that cardiologists and lipidologists face in daily practice is how to best approach the elderly patient with dyslipidemia. Joining Dr. Alan Brown for special considerations in this population and guideline-based recommendations for management is Joyce Ross, certified registered nurse practitioner, clinical lipid specialist, and President-Elect of the National Lipid Association.
Supported by an Educational Grant from AstraZeneca.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown welcomes Dr. Don Wilson, Endocrinologist at Cook Children's Health Care System, Fort Worth, Texas. Dr. Wilson will review dyslipidemia in children and adolescent patients. Key points of their discussion will cover the association between abnormal lipid levels in children and an increased lifetime risk of atherosclerotic CVD, as well as, the CVD risk factors present in children and how it tracks from childhood to adulthood.
Supported by an Educational Grant from AstraZeneca.
Supported by an Educational Grant from AstraZeneca. - See more at: https://reachmd.com/programs/lipid-luminations/million-hearts-initiative-dr-janet-wright-executive-director/7439/#sthash.aVHL9OOn.dpuf Supported by an Educational Grant from AstraZeneca. - See more at: https://reachmd.com/programs/lipid-luminations/million-hearts-initiative-dr-janet-wright-executive-director/7439/#sthash.aVHL9OOn.dpuf
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
In this session of Lipid Luminations, host Dr. Alan Brown welcomes Dr. Merle Myerson, founder and director of the Cardiovascular Disease Prevention Program, Lipid Clinic, Pre-Exercise Heart Screening Program, and Cardiology Section/Institute for Advanced Medicine (HIV) at Mount Sinai St. Luke's and Mount Sinai Roosevelt Hospitals. Dr. Myerson reviews the guidelines for prevention, diagnosis, and management of dyslipidemia in patients with HIV.
Host: Maurice Pickard, MD
Stress and other negative emotions contribute to about 25 percent of heart attacks. But recent cutting-edge research shows that positive emotions can cause a chemical change in your body that directly improves your overall cardiovascular health. Dr. Maurice Pickard welcomes Dr. Michael Miller to discuss his book, Heal Your Heart: The Positive Emotions Prescription to Prevent and Reverse Heart Disease. Dr. Miller is a Professor of Cardiovascular Medicine, Epidemiology, and Public Health at the University of Maryland School of Mediicne and is the Director of the Center of Preventive Cardiology.
Host: John J. Russell, MD
Dr. Bruce Fye's unique book, Caring for the Heart: Mayo Clinic and the Rise of Specialization, weaves together three important themes. It describes major developments in the diagnosis and treatment of heart disease in the twentieth century, explains how the Mayo Clinic evolved from a family practice in Minnesota into one of the world's leading medical centers, and reveals how the invention of new technologies and procedures promoted specialization among physicians and surgeons. Join Dr. John Russell in overviewing with Dr. Fye this pivotal epoch in American medical history.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Janet Wright, MD
Heart disease and stroke are two of the leading causes of death in the United States. The Department of Health and Human Services, with several key partners, launched the Million Hearts national public-private initiative. Million Hearts aims to prevent one million heart attacks and strokes over five years through behavioral changes and clinical interventions. Host Dr. Alan Brown welcomes Dr. Janet Wright, Executive Director of Million Hearts in Washington, DC.
Supported by an Educational Grant from AstraZeneca.
Host: Brian P. McDonough, MD, FAAFP
Stress has long been associated with cardiovascular risk, but few studies have connected stress with worsened recovery rates after heart attacks. Moreover, the recently published discovery that women with mental stress may suffer worse outcomes recovering from heart attacks than men under similar conditions raises more questions than answers. What are the possible mechanisms by which this gender disparity in outcomes may occur, and how can clinicians help mitigate this risk? Dr. Brian McDonough welcomes Dr. Nieca Goldberg, cardiologist and director of the Joan H. Tisch Center for Women's Health at NYU Langone Medical Center.
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA
One in two adults in the United States has a total cholesterol over 200 mg/dL, while one in three has diagnosed cardiovascular disease. The ACC/AHA's recently released Lipid Guidelines have provided new recommendations for treatment of dylipidemia, but they have also created some controversies and confusion in expert circles around best practices moving forward. Helping to dissect these Guidelines and shed light on the rationales behind the new recommendations is Joyce Ross, certified registered nurse practitioner and clinical lipid specialist.
Host: Jennifer Caudle, DO
As a family practictioner, host Dr. Jennifer Caudle's passions is the health of her adolescent patients. Obesity is all too prevalent among adolescents, and with this comes a concern about hypertension. And, to discuss the great concern, Dr. Caudle welcomes Dr. Julie Ingelfinger, Deputy Editor of The New England Journal of Medicine and Professor of Pediatrics at Harvard Medical School. Dr. Ingelfinger is the author of the article, "The Child or Adolescent with Elevated Blood Pressure," which was published a recent issue of the New England Journal of Medicine.
Host: Lee Freedman, MD
How does surgery and stenting for carotid lesions help prevent stroke? What are the latest approaches, clinical trials, and philosophy for dialysis access for patients? Host Dr. Lee Freedman welcomes Dr. Benjamin Jackson to answer these questions and the latest innovations in vascular surgery at the University of Pennsylvania Hospital. Dr. Jackson is an Assistant Professor of Surgery in Radiology at the University of Pennsylvania Hospital.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
As many as 25% of patients taking statins may experience side effects. How should clinicians respond to the broad spectrum of side effects and variable severities reported? Host Dr. Alan Brown welcomes Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology at Duke University School of Medicine, to discuss statin intolerance and the most effective methods for counseling patients who experience this issue. Dr. Guyton's team has developed approaches that help many patients who have trouble taking statin drugs find alternative ways to lower their low-density lipoprotein (LDL) levels. Dr. Guyton is recognized nationally as an expert in clinical management of lipid disorders and is known for his earlier work on lipid deposition in the arterial wall.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
A paradigm shift in the management of lipid disorders has been witnessed of late based on evidence reviews by the AHA and the ACC. Where the clinical dogma once focused on targeting specific lipoproteins, clinicians are now trending toward using appropriate dosages of statins for lowering non-HDL cholesterol. What are the ramifications of this change in approach, and how does the NLA weigh in on recommendations for targets and goals? To address these and other questions, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
What's the evidence for LDL and other non-HDL targets for primary and secondary prevention of heart disease? What are the comparative benefits versus toxicities of all lipid-lowering medications in clinical use? Addressing these and other questions from the standpoing of recent NLA recommendations is Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL.
Produced in partnership with
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Carl Orringer, MD, FACC, FNLA
What are some of the causes of high triglycerides? What is the biggest health risk? And, for these patients, at what level is the risk greater for developing pancreatitis and coronary artery disease? Host Dr. Alan Brown welcomes Dr. Carl Orringer, Associate Professor of Medicine at the Cardiology Division, University of Miami Medical Center and Director of the Preventive Cardiovascular Medicine and LDL apheresis program. In this edition of Lipid Luminations, Dr. Orringer will discuss the management of the patients with triglycerides 200-499 mg/dl.
The Gender, Sexuality and HIV Prevention Center at Ann & Robert H Lurie Children's Hospital of Chicago is the first of its kind facilty for adolescent patients. Host Dr. Jennifer Caudle welcoms the center's director, Dr. Robert Garofalo. Dr. Garofalo will share the center's mission of supporting multidisciplinary academic subjects including sexual health, gender, sexuality, HIV prevention and health disparities which affect adolescent and young adult populations at risk of acquiring HIV. The Center partners with similar organizations throughout the country in creating an environment where clinicians, academics and scientists can collaborate to design projects with public health significance.
Robert Garofalo, MD, MPH, is Professor of Pediatrics and Preventive Medicine at Northwestern University Feinberg School of Medicine. He is also an Attending Physician at Lurie Children's, where he directs the Adolescent/Young Adult HIV Program. Dr. Garofalo is a national authority on LGBT health issues, adolescent sexuality, and HIV clinical care and prevention.
Host: Tim Rush
As a busy health professional doing what you love, you still need to think about how to grow your business. How do you balance the clinical and business-related demands? Host Tim Rush welcomes Michael Weber, MD, cardiologist and entreprenuer, who shares his story about developing a new medical app that has helped grow his business. Dr. Weber is a cardiac electrophysiologist on Long Island, New York and the developer of the DirectLineMD app. For more information, you can visit www.directlinemd.com
Download and listen to the conversation today!
Guest: Anne Goldberg, MD
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown is joined by Anne Goldberg, MD, Associate Professor of Medicine at Washington University School of Medicine and a member of the ACC/AHA Blood Cholesterol Guidelines Panel. Dr. Goldberg will provide a review of the panel assembled by National Heart, Lung, and Blood Institute to construct integrated guidelines for cardiovascular risk reduction. She will also address the controversy regarding the ACC/AHA recently published risk assessment and cholesterol guidelines.
Download and listen today!
Sponsored by
Guest: Kevin C. Maki, PhD, FNLA, CLS
Guest: Carl Orringer, MD, FACC, FNLA
Guest: Harold Bays, MD, FNLA
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Matthew Ito, PharmD, FNLA
Host Dr. Alan Brown is joined by an expert panel to discuss the NLA's latest draft document that will serve as recommendations to clinicians for the management of patients with dyslipidemia. The National Lipid Association's goal was to harmonize guidelines among what has been presented in the past by the ATP panel, the American College of Cardiology/American Heart Association Guidelines, and those also released in 2013 by the International Atherosclerosis Society. The NLA reaffirms the importance of understanding targets of treatment and goals for patients.
Our expert panelists:
- Harold Bays, MD, FNLA - Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center; co-author of the National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia and co-author of the American Society of Bariatric Physicians Obesity Algorithm
- Matthew Ito, PharmD, FNLA - Professor of Pharmacy Practice and Director of the Cardiovascular Pharmacodynamics Laboratory at Oregon State University/Oregon Health & Science University; member of the National Lipid Association Expert Panel on the Diagnosis and Treatment of Familial Hypercholesterolemia and the Recommendations for Patient-Centered Management of Dyslipidemia
- Carl E. Orringer, MD, FACC, FNLA - Associate Professor of Medicine, Cardiology Division at the University of Miami Medical Center; Editorial reviewer …
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Is there a patient age at which statin therapy should be discontinued? Likewise, what does the current evidence tell us about initiating vs not initiating statin therapy in older patients? Joining Lipid Luminations to discuss these and other important questions is Dr. W. Virgil Brown, Charles Howard Candler Professor of Medicine Emeritus at Emory University School of Medicine in Atlanta, Georgia.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Joining host Dr. Alan Brown is Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology of the Division of Medicine-Endocrinology and Metabolism at Duke University School of Medicine. Their discussion will focus on data and results from HPS-2 THRIVE, a large-scale study comparing the use of statins and niacin versus statins alone. THRIVE stands for the Treatment of HDL to Reduce the Incidence of Vascular Events.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Health information technologies have evolved dramatically from simplistic documentation devices early on to sophisticated drivers of quality patient care today. This emergence is having a particularly positive effect on treatment for dyslipidemia. Joining host Dr. Alan Brown to reflect on a recent NLA manuscript of HIT's impact toward adherence to lipid therapy is Dr. Jerome Cohen, Emeritus Professor of Internal Medicine at Saint Louis University School of Medicine and Director of Preventative Cardiology Program at the Saint Louis University Health Sciences Center. Dr. Cohen has been active in cardiovascular research for more than two decades.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Joining host Dr. Alan Brown is Michael B. Bottorff, Pharm.D., Professor and Chair in the Department of Pharmacy Practice at South College School of Pharmacy in Knoxville, Tennessee. Dr. Bottorff will be reviewing generic medications, from manufacturing processes to approval measures.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Speaking with host Dr. Alan Brown on the state of genetic testing for familial hypercholesterolemia (FH) is Dr. Joshua W. Knowles, MD, PhD, Instructor of Cardiovascular Medicine at Stanford University and Attending Physician of the Stanford Center for Inherited Cardiovascular Disease Familial Hypercholesterolemia (FH) Clinic.
Guest: Todd Kerwin, MD, FACC, FASNC
Host: Sandeep Nathan, MD, MS
This interview recorded live at a Prova Education activity in New York City features Drs. Todd Kerwin and Sandeep Nathan as they discuss the Contemporary Management of Acute Coronary Syndromes. They will review treatment, management and prevention of secondary acute coronary syndromes in specific populations. This educational conversation delivers real-life discussion around the difficulties of managing a patient with acute coronary syndromes and overcoming barriers to optimal care.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Dr. Alan Brown is joined by Dr. Bart Duell, director of the Lipid Disorders Clinic at the Oregon Health and Sciences University and one of the top winners in the NLA Abstracts program, to discuss research updates in Familial Hypercholesterolemia (FH).
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Dr. Alan Brown is joined by Dr. Thomas Dayspring, Director of Cardiovascular Education for the Foundation for Health Improvement and Technology in Richmond, VA and clinical assistant professor of medicine at the UMDNJ - NJ Medical School. He is also a Fellow of both the American College of Physicians and the National Lipid Association. The two discuss Dr. Dayspring's research on discordances between LDL-P and ApoB, two biomarkers that are otherwise thought to correlate well with one another.
Host: The Endocrine Society
Diabetes Highlights from ENDO, the 95th Annual Meeting of The Endocrine Society. The Endocrine Society is the world's oldest, largest, and most active organization devoted to research on hormones and the clinical practice of endocrinology. In this program, you will hear from global thought leaders on the important role of diabetes in your practice, new technologies, emerging therapies and research.
Diabetes Diagnosis and Management is presented by The Endocrine Society and its Hormone Health Network. This annual workshop focuses on current issues in clinical diabetes management and provides state-of-the art updates. The complete Diabetes Diagnosis and Management recording is free on endosessions.org. To hear more from ENDO 2013, visit endosessions.org
Program Highlights Listen to hear these global thought leaders:
- Carol Wysham, MD, University of Washington School of Medicine, Spokane, WA provides an overview of the key presentations from this year's meeting
- Robert Eckel, MD, University of Colorado, Aurora, CO shares his research on the emerging cardiovascular disease risk factors
- Edmond Ryan, MD, University of Alberta, Edmonton, Alberta, Canada discusses the screening and diagnosing of gestational diabetes
- Steven Kahn, MB, ChB, VA Puget Sound Health Care System, Seattle, WA, reviews the relationship of the …
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Dr. Alan Brown welcomes Dr. Daniel J. Rader, Cooper-McLure Professor of Medicine and Pharmacology and Chief of the Division of Translational Medicine and Human Genetics at the Perelman School of Medicine at the University of Pennsylvania. Their discussion focuses on the clinical diagnosis, genetic complexity and prevalence of HoFH while exploring the current and novel modalities available to help HoFH patients achieve their LDL goals.
Produced in Partnership with
Supported by an Educational Grant from
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Dr. Harold Bays, Chair for the National Lipid Association's expert panel on Adiposity, Obesity, and Dyslipidemia, discusses with host Dr. Alan Brown the panel's consensus statement published in the Journal of Clinical Lipidology.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Obesity is associated with systemic inflammation and oxidative stress, the leading steps towards development of atherosclerosis. Myloperoxidase (MPO) mediated oxidative damage of high-density lipoprotein (HDL) leads to a dysfunctional HDL which likely becomes pro-atherogenic. But, what happens in our adolescent patients? Monica Marin, MD, pediatric endocrinology fellow at the University of Oklahome Health Sciences Center and winner of the NLA Young Investigator Award, investigated the cardiovascular risk factors that are present in childhood and the importance of understanding the impact of oxidized HDL.
Download and listen today!
Produced in Partnership with
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Joining Dr. Alan Brown is Revathi Balakrishnan, MD, MPH, a general cardiology fellow at NYU and winner of the NLA Young Investigator Competition. Dr. Balakrishnan's research, titled "Prevalence of unrecognized prediabetes, diabetes and metabolic syndrome in patients undergoing non-urgent PCI," found that nearly 1 out of every 10 patients admitted to the NYU cardiac catheterization lab had diabetic hemoglobin A1c levels (6.5 and over) without a prior diagnosis of diabetes. An even larger proportion had prediabetes (57%) and metabolic syndrome (54%). Put another way, only 30% of the patients undergoing PCI had a normal glycemic status on admission. Drs. Balakrishnan and Brown reflect on these concerning results and discuss the need for a call to action among preventive cardiologists.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
There may be something unique about the avocado, far beyond its monosaturated fat content. Li Wang, graduate student at Penn State University and winner of the NLA Young Investigator Award, investigated this notion with a clinical study monitoring the effects of eating one avocado every day on risk factors for cardiovascular disease compared to a similar moderate fat diet without avocados, an average American diet, and a low-fat diet. Tune in for this discussion revealing her thought-provoking findings.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown is joined by David Tehrani, MS, a medical student at the University of California - Irvine School of Medicine and winner of the NLA's Young Investigator Competition for his research into the negative impact of inflammation on HDL's known cardioprotective effects. Tune in for new understandings on HDL and the inflammatory biomarkers attenuating its protective functions.
Guest: Janet Maxson, PhD, FNP
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan S. Brown welcomes Janet Maxson, NP, PhD, iPresident-Elect of the Midwest Lipid Association and the Director Women's Health at Minot Health & Wellness in Minot, North Dakota. Dr. Maxson is also a Fellow of the American Heart Association Council of Cardiovascular Nursing and the National Lipid Association. Dr. Maxson will review which calcium supplements are better for women, how much calcium is needed, and define the screening guidelines that are in place to screen women's bones in the context of heart disease.
Tune in for another great interview from Lipid Luminations!
Guest: Lee Philip Shulman, MD, FACOG, FACMG
Omnia Education's and Prova Education's combined Capstone Conference in New York took advantage of common interests across all learners, addressing clinical trends and future directions across a broad spectrum of primary care and women's health topics. Joining host Lawrence Sherman to reflect on highlights from the combined agenda of Omnia's Stages in Women's Health® and Prova's Evolving Practice of Primary CareTM is Dr. Lee Shulman, Professor of Obstetrics and Gynecology at Northwestern University's Feinberg School of Medicine and Chairman of the conference program.
Host: Matt Birnholz, MD
This session of Grand Rounds Nation is provided by the American College of Osteopathic Family Physicians (ACOFP), and features Dr. Robert Hasty speaking on anticoagulation therapy guidelines for nonvalvular atrial fibrillation. Topics explored in depth include first vs second line drug regimens, updates on "golden windows" for initiating therapies, and effective risk stratification methods in practice.
Host: Matt Birnholz, MD
This session of Grand Rounds Nation is provided by the American College of Osteopathic Family Physicians (ACOFP), and features Dr. Anthony Brown, clinical assistant professor of medicine at the University of Medicine and Dentistry of New Jersey.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: William S. Harris, PhD
Host Dr. Alan Brown welcomes Dr. William "Bill" Harris on an important discussion facing our colleagues and ptients- "Are Fish Oils still cardioprotective?". Dr. Harris will address the recent randomized trials, how the trials differ from those done in the 1990s, and how clinicians should utlize the information in treating their patients.
Dr. William "Bill" Harris holds a PhD in Nutritional Biochemistry from the University of Minnesota. His research has focused on human lipid and lipoprotein metabolism, especially as they are affected by omega-3 fatty acids. He has been the principal investigator on 5 omega-3 related NIH grants, and since 2004 has been evaluating the RBC "omega-3 index" as a new risk factor for cardiovascular and neuropsychiatric diseases.
Guest: Peter Toth, MD
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown is joined by Peter P. Toth, MD, PhD, director of preventive cardiology in Sterling Rock Falls Clinic and clinical professor at the University of Illinois School of Medicine in Peoria, Illinois. Dr. Toth is the current president of the National Lipid Association.
One of the most intensively studied drugs are statins. However, will statins continue to be the miracle drugs that health care professionals and patients rely on? What are statins current role in therapy for dyslipidemia patients? In this discussion, Dr. Toth will address these questions. He will also review the new therapies for lowering LDL and whether LDL should continue to be the target for risk assessment and treatment.
Brought to you by:
Guest: Benjamin J. Ansell, MD, FACC, FACP, FNLA
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown welcomes Benjamin Ansell, MD, professor of medicine and cardiology at University of Califronia at Los Angeles, CA and co-director of the Cholesterol and Hypertension Management Program at UCLA. Dr. Ansell reviews the latest trials: dal-OUTCOMES and AIM-HIGH. Dr. Ansell will address the objectives and study designs of both studies and explain why the studies were stopped early. Drs. Brown and Ansell also discuss the future of HDL therapy.
Brought to you by:
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Spencer Kroll, MD, PhD
The Food and Drug Administration has warned that patients taking cholesterol-fighting statins face a small increase in the risk of higher blood-sugar levels and of being diagnosed with diabetes. There has been conflicting information from several large trials about the effects of statin therapy on the development of diabetes and glycemic control.
Join host Dr. Alan Brown and Dr. Spencer Kroll, diplomate of the American Board of Clinical Lipidology and a board certified Internist. He also serves on the board of directors of the Northeast Lipid Association and runs The Cholesterol Treatment Center, a lipid clinic in Marlboro, New Jersey.
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Host: Matt Birnholz, MD
Primary care is the mainstay for managing patients with hyperlipidemia or mixed dyslipidemia. But in practice we don't often encounter it in isolation; comorbid conditions such as diabetes, hypertension, and coronary artery disease follow dyslipidemia like common catch phrases, so it becomes necessary to understand this problem in the context of complicated patients. What do we need to know to optimize patient outcomes? Host Dr. Matt Birnholz is joined by Dr. Gregory Pokrywka, Director of Baltimore Lipid Center and Assistant Professor of Medicine at Johns Hopkins School of Medicine, to discuss this issue.
Guest: Michael H. Davidson, MD
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Is there a difference between biomarker cardiovascular risk assessment for broad population studies vs the role in personalized medicine? And, in individual patients, if a difference is found between the Framingham score and the biomarker risk assessment, which is more likely to correctly predict risk? Host Dr. Alan Brown talks with Dr. Michael Davidson, director of preventive cardiology and associate vice chairman for continuing medical education at the University of Chicago, about the role of biomarkers in improving cardiovascular risk prediction and guiding treatment, compared to traditional risk factor assessment.
Guest: George L. Bakris, MD
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Host Dr. Alan Brown talks with Dr. George Bakris, director of the Hypertensive Disease Unit at the University of Chicago Pritzker School of Medicine, about lipid management in the hypertensive patient and its particular relevance to patients with chronic kidney disease. How do cardiovascular events differ in chronic kidney disease patients compared to the general population? And do statins work in dialysis patients? They discuss these questions and the conclusions of the Study of Heart and Renal Protection (SHARP).
Host: Matt Birnholz, MD
Presenting this session of Grand Rounds is Dr. Gordon Ewy, professor and chief of cardiology at the University of Arizona College of Medicine.
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Host: Lee Freedman, MD
Guest: Grace Wang, MD, FACS
Dr. Grace Wang, vascular surgeon in the division of vascular and endovascular surgery at Penn Medicine, discusses aortic disease from a surgeon's perspective, with host Dr. Lee Freedman. Among the topics they explore are the importance of history and physical exams, imaging modalities, genetic components, management of anneurisms, surveillance, outpatient and inpatient care.
Guest: James Falko, MD
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
About 1 in 500 people have familial hypercholesterolemia (FH), the genetic disorder characterised by very high levels of low-density lipoprotein in the blood. Host Dr. Alan Brown talks to Dr. James Falko, professor of medicine in the division of endocrinology, metabolism and diabetes at the University of Colorado, Denver, about technology behind LDL apheresis to remove LDL cholesterol from blood. They cover the frequency of the procedure, possible complications, and what the data shows about the benefits of LDL apheresis in FH patients with refractory hypercholesterolemia. Dr. Falko also directs physicians to resources for locating LDL apheresis sites in the United States and Canada.
Brought to you by:
Host: Matt Birnholz, MD
Presenting this session of Grand Rounds is Dr. Mark J. Friedman, clinical professor of medicine and director of the Heart Failure Program at the University of Arizona.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Host: Janet Wright, MD
Guest: Gary Mintz, MD
Acute coronary syndromes in patients who have undergone percutaneous coronary intervention is the subject of the conversation between guest Dr. Gary Mintz, chief medical officer of the Cardiovascular Research Foundation, an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education, and host Dr. Janet Wright. How often do patients who have an acute coronary syndrome have a recurrent event? Their discussion includes protocols, paramaters and outcomes of the PROSPECT trial. The use of ultrasound as well as angiography are also discussed in context to help identify unstable coronary plaques in order to prevent adverse coronary events.
Guest: Anne Goldberg, MD
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
The National Lipid Association Foundation is emphasizing awareness of the most common inherited form of high cholesterol, familial hypercholesterolemia. Endocrinologist Dr. Anne Goldberg, talks with host Dr. Alan Brown about how to recognize and treat this hereditary cause of early onset atherosclerosis. Research has shown that statin treatment should begin when patients are very young. How early in life can we start screening and treating children, and are there differences to consider when treating young male versus female patients?
Brought to you by:
Host: Matt Birnholz, MD
The American College of Cardiology's 60th Annual Scientific Session and Expo, held April 2 to 5 in New Orleans, attracted approximately 30,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in cardiology. The conference highlighted recent advances in the treatment, management, and prevention of cardiovascular diseases, with presentations also focusing on novel drugs and surgical approaches to improve the quality of care for patients with cardiovascular diseases.
Guest: Joseph Cleveland, MD
Host: Janet Wright, MD
Cardiac surgery can improve quality of life, but it also poses risks for patients over the age of 65. Can a screening test as simple as walking speed predict the outcomes of cardiac surgery for our older patients? Dr. Janet Wright hosts this discussion.
Host: Lisa Dandrea Lenell, PA-C, MPAS, MBA
Guest: Nguyen Park, MS, PA-C
Almost 4 million people in the US have high triglycerides. What can you do to help improve your patients' health? Nguyen Park, clinical assistant professor in the physician assistant studies program, at Wayne State University in Detroit, Michigan, joins host Lisa Dandrea Lenell to discuss the benefits of fish oil for treating hypertriglyceridemia. They also look at the risk factors, causes and other treatment options for this very common disease.
Guest: Thomas C. Wozniak, MD
Host: Aaron Carroll, MD
Currently, 3 to 5 million people per year suffer from heart failure in the United States; one-third of these patients suffer from Class III or Class IV heart disease. Host Dr. Aaron Carroll welcomes Dr. Thomas Wozniak, surgical director of the Indiana University Health Thoracic Transplant Program. Dr. Thomas discusses the advanced heart failure patient, and who is a candidate for ventricular assist device (VAD) therapy and cardiac transplantation and considerations about timing.
Guest: Carl Orringer, MD, FACC, FNLA
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
The Medicare donut hole, underemployment, and loss of employment can all put patients in situations that make affording lipid medications difficult to impossibl. Host Dr. Alan Brown talks to Dr. Carl Orringer, director of the Lipid Clinic and Preventive Cardiovascular Medicine Program at University Hospitals Case Medical Center, about strategies for working with patients who are having trouble affording their lipid medications. The solutions include pill-splitting when appropriate, discount drug stores, and novel recycled drug repository programs which are available in 38 states. What can we do to help patients whose financial circumstances do not only make medication adherence challenges, but are also related to an unhealthy diet and limited access to opportunities for physical activity.
Brought to you by:
Host: Janet Wright, MD
Guest: Thad Waites, MD
Obesity is a nationwide epidemic, but this is nowhere more apparent than in Mississippi, which was ranked as the state with the highest obesity rate in 2009 by the Centers for Disease Control. How does the obesity issue in Mississippi mirror that of the rest of the nation, and what efforts are underway to address this public health problem? Dr. Thad Waites, director of the cardiac catheterization lab at Forrest General Hospital in Hattiesburg, Mississippi, and interventional cardiologist at the Hattiesburg Clinic, talks about how each player in the healthcare community can target the obesity epidemic. What initiatives and projects are demonstrating success in lowering obesity rates? Dr. Janet Wright hosts.
Produced in Cooperation with
Guest: Michael H. Davidson, MD
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Lipid Luminations host Dr. Alan Brown and his guest, Dr. Michael Davidson, discuss the predictive value of lipid biomarkers and inflammatory markers, particularly when compared with traditional risk factors, as well as the process of developing consensus on the use of novel risk factors.
Brought to you by:
Host: Janet Wright, MD
Guest: Robert Harrington, MD
Recent studies have raised doubts about the efficacy of some common treatments for cardiovascular disease, including: the use of PFO closures (based on the CLOSURE trial); some methods of cardiac resynchronization therapy (or CRT, based on the SMART-AV trial); telemonitoring for patients with congestive heart failure (based on the Tele-HF trial); and doubling the dose of clopidogrel in patients who had a poor response to the drug after percutaneous coronary intervention (based on the GRAVITAS trial). Dr. Robert Harrington, director of the Duke Clinical Research Institute at Duke University Medical Center in Durham, North Carolina, reviews the evidence in each of these trials, and gauges the clinical impact of their findings. Dr. Janet Wright hosts.
Produced in Cooperation with
Host: Janet Wright, MD
Guest: Caldwell Esselstyn, Jr., MD
Beta blockers, anticoagulants, stenting procedures and bypass surgeries: these are all crucial cornerstones of cardiology that have saved and improved the quality of lives for our patients, yet the underlying causes of coronary artery disease aren't addressed by interventions and medications. Can we prevent and maybe even reverse heart disease by prescribing a plant-based diet? Dr. Caldwell Esselstyn, director of the cardiovascular prevention and reversal program at the Cleveland Clinic Wellness Institute and author of the book, Prevent and Reverse Heart Disease, says heart disease is "an essentially benign, food-borne illness," that can be prevented by adhering to a diet based around plants. What evidence supports this idea? Join us for part 1 of our two-part interview with Dr. Esselstyn. Dr. Janet Wright hosts.
For Part 2 of this interview, click here >>
Produced in Cooperation with
Host: Janet Wright, MD
Guest: James Scheulen, PA-C
Guest: Jeffrey Trost, MD
Door-to-balloon time for a patient with ST-segment elevation myocardial infarction (or STEMI) should be less than 90 minutes. Wireless electrocardiography (or EKG) programs around the country are helping to reduce door-to-balloon time by transmitting EKG data to hospitals via broadband internet, where a specialist at the hospital makes a diagnosis and prepares to treat the incoming patient. What are some of the challenges, and advantages, of such programs? Mr. Jim Scheulen, chief administrative officer for the Johns Hopkins Department of Emergency Medicine and president of Johns Hopkins Emergency Medical Services, and Dr. Jeffrey Trost, assistant professor in cardiology, director of the Cardiac Catheterization Laboratory and director of the Interventional Cardiology Program at Johns Hopkins Bayview Medical Center, helped create a Baltimore consortium of hospitals that donated wireless EKG technology to the city's paramedic units. How effective has the Baltimore program been at improving treatment for MI patients, and how is this program similar to others around the country? Dr. Janet Wright hosts.
Produced in Cooperation with
Guest: Ken Fujise, MD
Host: Janet Wright, MD
Targeted molecular therapy has been successful in cancer therapeutics. How might this approach be applied in cardiology to prevent the development of atherosclerosis? Dr. Ken Fujise, chief of cardiology at University of Texas Medical Branch, where he is also professor of medicine and biochemistry and molecular biology, talks about his preliminary research investigating the role of fortilin in the progression of atherosclerosis and subsequent coronary artery disease. What are the prospects for development of anti-fortilin medication to prevent or slow atherosclerosis? Dr. Janet Wright hosts.
Produced in Cooperation with
Guest: Steven Wittlin, MD
Host: Lee Freedman, MD
It is often thought that patients with diabetes have more "silent" heart disease than patients without diabetes: Coronary artery disease is a leading cause of death among these patients. But is screening all asymptomatic patients with diabetes for the condition prudent, or should we exercise caution when considering cardiac screening? Dr. Steven Wittlin, associate professor of medicine and clinical director of the endocrine/metabolism division at the University of Rochester in New York, makes screening recommendations based on the recent Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Dr. Lee Freedman hosts.
Guest: Prediman Shah, MD
Host: Janet Wright, MD
It is apparent to most physicians that patients at high risk for having a cardiovascular event should be screened, but what about those patients who fall into the intermediate risk category (classified using the Framingham risk score)? Dr. Prediman Shah, director of the division of cardiology at Cedars-Sinai Heart Institute in Los Angeles, suggests that screening asymptomatic, intermediate-risk patients for subclinical atherosclerosis using non-invasive imaging might be beneficial. Dr. Shah also discusses the limitations of relying solely on the Framingham risk score, and recommends additional ways to classify a patient's risk for developing a cardiovascular event. What specific screening tests are best for detecting subclinical atherosclerosis? Dr. Janet Wright hosts.
Produced in Cooperation with
Guest: Ralph LaForge
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Joining host Dr. Alan Brown, Ralph LaForge, clinical exercise physiologist at Duke University in the department of endocrinology, and senior faculty consultant to the diabetes division of the US Indian Health Service, discusses the health issues of the Native American population, and some of the novel treatment protocols being developed.
Brought to you by:
Guest: Donald Sefcik, MD
Host: Lisa Dandrea Lenell, PA-C, MPAS, MBA
After many years of discussion, the National Commission on Certification of Physician Assistants (NCCPA) will offer PAs Certificates of Added Qualification in 5 specialties, beginning in 2011. Dr. Don Sefcik, chairman of the NCCPA, joins host Lisa Dandrea Lenell to explain what it takes to obtain certification, what the benefits are to PAs, and why the NCCPA decided to institute the certification now, with the nation's healthcare system in flux.
Guest: Jennifer B. Green, MD
Host: Steven Edelman, MD
What is known about the relationship between glucose control and cardiovascular disease in diabetes? The recent Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial provides some interesting results on the relationship between type 2 diabetes and silent myocardial infarction. Join host Dr. Steven Edelman and his guest, assistant professor of medicine in the division of endocrinology, metabolism and nutrition at Duke University, Dr. Jennifer Green, as they discuss the role of glycemic control to cardiovascular disease in both sexes.
Host: Janet Wright, MD
Guest: Christopher O'Donnell, MD, MPH
We know that genes play a role in cardiovascular health, but new research has identified specific DNA regions that are associated with risk factors for coronary heart disease. It's estimated that 30-50% of cardiovascular health is influenced by family history or genetics, while the rest is influenced by other environmental factors, diet and exercise. How might these new genetic discoveries lead to new treatment options? Dr. Christopher O'Donnell, associate director and scientific director of the SHARe Project of the Framingham Heart Study at the National Heart, Lung and Blood Institute, and associate clinical professor of medicine at Harvard Medical School in Massachusetts, talks about his work genotyping the single-nucleotide polymorphisms of large cohort study participants. How are genome-wide association studies leading to discovery of new genes associated with various diseases, and will these findings move us into a new era of prevention and treatment of cardiovascular disease? Dr. Janet Wright hosts.
Host: Janet Wright, MD
Guest: Mark Hlatky, MD
Implantable cardioverter defibrillators, or ICDs, can be life saving for patients after myocardial infarction, but are also costly and may not be appropriate for all of the hundreds of thousands of patients who have had MI. Which subsets of patients might benefit most from ICDs, and might prophylactic use of ICDs early after MI reduce the risk of cardiac death? Dr. Mark Hlatky, professor of medicine and professor of health research and policy at Stanford University School of Medicine, weighs the comparative-effectiveness research on the efficacy of ICDs for patients early after MI, versus waiting a few months before implanting ICDs or trying other forms of therapy. Outside of implantable devices, what else can physicians do to reduce the risk of death after MI? Hosted by Dr. Janet Wright.
Produced in Cooperation with
Guest: Sanjay Kaul, MD, MPH
Host: Janet Wright, MD
Atrial-fibrillation, or a-fib, affects nearly 2.5 million patients in the US, and is one of the more common forms of arrhythmia. The antiarrhythmic armamentarium has been expanded to include dronedarone, which was recently approved by the FDA for the treatment of a-fib. What's the efficacy and safety of dronedarone, compared to other antiarrhythmic agents, and how should you use it? Dr. Sanjay Kaul, director of the Vascular Physiology and Thrombosis Research Laboratory at the Burns and Allen Research Institute at Cedars-Sinai Medical Center in Los Angeles, describes the profile of patients who should be considered candidates for dronedarone therapy. Will dronedarone replace the current gold standard for treating a-fib, amiodarone, and if not, where does dronedarone fit into the management algorithm for a-fib? Dr. Janet Wright hosts.
Produced in Cooperation with
Host: Janet Wright, MD
Guest: Sidney Smith Jr., MD
New evidence strengthens the link between air pollution and heart disease. How strong is the data suggesting a causal relationship between the two? Dr. Sidney Smith, professor of medicine and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina in Chapel Hill says there are two areas of interest in determining the effect of air pollution on the heart. One area being examined is whether air pollution can trigger acute cardiac events, and the other is whether chronic exposure to air pollution can cause the development of long-term cardiovascular disease. Which patients are most at risk for developing cardiovascular health problems from exposure to particulate matter, and how can patients limit their risk of adverse cardiovascular disease-related events from air pollution, even in urban areas? How does heavy air pollution in developing countries or during exercise impact the heart? Dr. Janet Wright hosts.
Produced in Cooperation with
Guest: Hosam Kamel, MD, MPH, CMD
Host: Eric Tangalos, MD
Heart failure is a common reason for hospitalization among older adults and long-term care patients. What strategies can help prevent a recurrence of heart failure, and what types of monitoring for exacerbations are most effective in prevention? How can physicians individualize therapy in this population? How crucial are blood pressure and hypertension control in managing patients with heart failure? Dr. Hosam Kamel, director of geriatrics and extended care, at St. Joseph’s Mercy Health Center in Hot Springs, Arkansas and associate clinical professor of geriatrics at the department of geriatrics at the University of Arkansas for Medical Sciences, discusses the goals of managing patients with heart failure in long-term care, and offers pragmatic advice for physicians in managing patients with heart failure. Dr. Eric Tangalos hosts.
Host: Janet Wright, MD
Guest: David Wilber, MD
Although medications are generally first-line therapy for patients with atrial fibrillation, or a-fib, adverse events or inadequate efficacy often make drug therapy suboptimal. How effective is catheter ablation, and should it be considered first-line therapy for some patients? Host Dr. Janet Wright talks with Dr. David Wilber, director of the Cardiovascular Institute and the George M. Eisenberg professor of cardiovascular sciences at Loyola University Chicago Stritch School of Medicine, about recent findings on the efficacy of catheter ablation for a-fib. What are the most significant risks to be aware of when considering catheter ablation therapy?